Browse site A to Z

Search results

Go To Advanced Search

Current funding calls

Description: Auto Generated Title Here you can find new grant funding calls from various funders. Links on the right will take you directly to other calls with specific key funders. Keep up-to-date with COVID-19 funding calls and resources The Health Research Authority is publishing details about all approved COVID-19 research studies, within their dedicated COVID-19 section. More information New research priorities identified for aerosol generating procedures related to COVID-19 New funding opportunities are likely to result from the identification of a new set of research priorities relating to the COVID-19 pandemic. Details will be published here as they are made available. Five new research priorities have been identified through the NIHR expert review process, with the purpose of providing evidence to understand and assess aerosol generation and the infective risk associated with individual AGPs as well as broader questions about airborne transmission of COVID-19 in healthcare settings. Understanding the fundamental aerobiology Including virus distribution and viability in airborne particles. Risk factors for transmissibility Understanding and quantifying the risk of transmissibility across multiple domains (including patient, procedure, environment, pathogen and healthcare professional factors) in order to generate a clinically applicable risk model. Mitigating precautions and their components Identifying which mitigating precautions are important and how they work: to include clinical efficacy testing of PPE, environmental measures (e.g. ventilation, filtration), and other barrier devices. Transmission of COVID-19 and other pathogens Investigating the contribution of inhalation versus inoculation for infection risk from AGPs and other healthcare interventions. Understanding infective risk perception, behaviours and acceptability of mitigation strategies This will include diverse groups of healthcare workers, patients and the public. More information EPSRC - healthcare technologies investigator-led grant Funder: Engineering and Physical Sciences Research Council Closing date: n/a - OPEN CALL Healthcare technologies investigator-led research grants are for researchers at UK higher education institutions, research council institutes, UKRI-approved independent research organisations and NHS bodies. We strongly encourage collaboration with relevant healthcare professionals, other researchers, industry, the public sector and other relevant partners. We are looking for researchers in engineering, physical sciences, information and communications technologies (ICT) and mathematical sciences who want to apply their expertise to healthcare challenges. Projects can range in size from small short-term grants to multi-million-pound research programmes lasting several years. There is no limit on the size of the grant or length of the project. We will award 80% of the full economic costs of the project, and your organisation must agree to find the balance. More information UKRI - addressing limitations in manufacturing nucleic acid therapeutics Funder: UKRI Closing date: n/a - OPEN CALL Apply for funding to set up a research consortium addressing challenges in the manufacture of nucleic acid therapeutics. Current manufacture challenges include but are not limited to: scale of production product purity, stereochemistry and reproducibility sustainable production novel chemistries synthesis efficiency analytical oligonucleotide characterisation. The consortium can include academic and industrial organisations in the UK and abroad. The lead organisation must be UK-based. More information NIHR - NICE rolling call for research studies addressing NICE research recommendations Funder: NIHR Closing date: various, see below The NIHR research programmes (EME, HTA, PHR and HS&DR) are interested in receiving applications to meet recommendations in research identified in NICE guidance published from 2015 onwards (for the purposes of this call, NICE guidance includes the following: clinical, social care, public health, technology appraisals, interventional procedures and diagnostics). Proposals must be within the remit of one of the participating NIHR research programmes and the primary outcome measure must be health related. Proposals must be within the remit of at least one of the following participating NIHR Programmes. However, applications which span the remit of one or more programme are welcome. Health Technology Assessment (deadline 05 January 2022) Public Health Research (deadline: 30 November 2021) Sight Research UK - translational research award Funder: Sight Research UK Closing date: 30 November 2021 Sight Research UK funds pioneering research into the causes of eye disease, in order to develop better prevention methods and more effective treatments for children and adults. The Translational Research Award supports research projects with a clearly defined pathway to achieving patient benefit. Its goal is to help to accelerate the translation of scientific findings to the early stages of development of new therapies, devices, and diagnostics. Sight Research UK welcomes projects that have robust commercial potential, likely to attract large scale follow-on funding from other charitable, statutory or industry funders. Eligible projects must: Be based on unmet clinical need. Aim to generate lead candidates for therapeutic applications. Be relevant to and highly promising in the clinical setting (these are not early stage, proof of concept studies, instead they have already shown that the idea might be used as therapy in man). Be focused on assessing properties such as potency, efficacy, selectivity, or bioavailability of compounds identified by previous research as potentially strong candidates for therapeutic applications. Have a clear pathway to apply for funding such as the MRC Confidence in Concept, MRC Development Pathway Funding Scheme type funding and other similar funding schemes. More information NIHR Public Health Research Programme - researcher-led workstream Funder: NIHR Closing date: 30 November 2021 The Public Health Research (PHR) Programme funds research to generate evidence to inform the delivery of non-NHS interventions, intended to improve the health of the public, and reduce inequalities in health. The Public Health Research Programme are accepting stage 1 applications to their researcher-led workstream. More information NIHR Public Health Research Programme - dementia research call Funder: NIHR Closing date: 30 November 2021 This National Institute for Health Research (NIHR) call invites proposals for dementia research to address important health and social care questions. Research could involve any aspect of prevention, diagnosis, treatment, support or care, and related health and social care services. Applications which involve investigators spanning a range of specialties are encouraged and partnership with national charities welcomed. The HTA and EME programmes are also featuring this research area - see below 7 December and 5 January. More information British Geriatrics Society - specialist registrar research start-up grants Funder: BGS Closing date: 30 November 2021 The British Geriatrics Society Specialist Registrar Research Start-Up Grant scheme provides grants to individuals who want to get a research project started. The aim is to allow young doctors to follow through ideas at relatively short notice, to enable advantage to be taken of unique or rare opportunities, and to provide short-term assistance to speculative and innovative research that may be at an early stage. The grants may support a complete project or, where appropriate, support a pilot study to enable an application for external project grant support to be made. The grants are eligible for National Institute for Health Research (NIHR ) non-commercial partner status. More information NIHR Development and Skills Enhancement Award Round 8 Funder: NIHR Closing date: 30 November 2021 The Development and Skills Enhancement Award (DSE) provides a maximum of 1 year of funding for post-doctoral NIHR Academy Members to gain skills and experience for the next phase of their research career. As an applicant you will be required to demonstrate the new skills and experience you hope to gain through the award, and how it will benefit your future career in research. More Information NIHR PHR Programme 21/560 - James Lind Alliance priority setting partnerships rolling call Funder: NIHR Closing date: 30 November 2021 The Public Health Research (PHR) Programme funds research to generate evidence to inform the delivery of non-NHS interventions, intended to improve the health of the public, and reduce inequalities in health. The JLA Priority Setting Partnerships facilitate patients, carers and clinicians to work collaboratively to identify research priorities in particular areas of health and care. Their aim is to ensure that health research funders are aware of the issues that are important to the people who need to use the research in their daily lives. The NIHR PHR programme recognises the importance of the research priorities identified by the James Lind Alliance Priority Setting Partnerships and is interested in receiving high-quality applications which address them More information MRC - advancing adolescent mental health and wellbeing research Funder: Medical Research Council Closing date: 1 December 2021 Apply for funding to help improve research in the field of ‘ adolescence, mental health and the developing mind ’ through: methodological innovation capability building This opportunity will support projects that help researchers in delivering more relevant, valid, reproducible, mechanistically informed, multi-level and translationally scalable research in adolescent mental health over the next decade. Outputs from these projects may also allow new research questions to be investigated. Proposals should: address a clear area of unmet need with regard to existing research methods, concepts, tools or measures identify innovative new approaches for conducting mental health and wellbeing research with adolescents. More information NIHR - Health Technology Assessment Programme, commissioned workstreams Funder: NIHR Closing date: 1 December 2021 21/532 Intensive Interaction for children and young people with profound and multiple learning disabilities 21/534 Surgical management of successfully reduced incarcerated inguinal hernia in children 21/535 Follow-up strategy after radical treatment for prostate cancer 21/536 Sodium bicarbonate in neonatal care 21/537 Neuroendoscopic lavage for preterm babies with post-haemorrhagic ventricular dilatation 21/538 Benefits and harms of reduced dose oral isotretinoin in the management of acne vulgaris 21/539 Benefits and harms of maintenance therapy for refractory acne vulgaris or previous relapses by reduced dose isotretinoin regimens 21/540 Pharmacological treatments for low back pain or sciatica 21/542 Medication to manage sexual preoccupation in sex offenders 21/552 Microsuction compared with irrigation to remove earwax Diabetes UK - small grants and project grants Funder: Diabetes UK Closing date: 1 December 2021 Diabetes UK aims to improve lives through pioneering research into all forms of diabetes and diabetes-related complications. The work they support helps us understand the causes of diabetes, bring about life-changing breakthroughs in care, treatment and prevention and brings us closer to a cure. The following calls are open for application: Project grants : For high quality, hypothesis driven diabetes research projects, lasting up to five years and costing less than £ 500,000. Current research priority areas are: (1) New glucose monitoring technologies in inpatient care; (2) Understanding the pathogenesis of diabetes that develops atypically, or in minority populations Deadline for applications: 01 December 2021 Early-Career Small Grants : supports early-career basic scientists and members of Allied Health Professions to undertake small research projects related to diabetes. The scheme will enable scientists at an early stage in their career to develop their work and go on to obtain additional grant funding from other organisations. Nurses, pharmacists and members of the Allied Health Professions who meet the eligibility criteria may apply through this scheme. Deadline for applications: 01 December 2021 Diabetes UK & Great Foundations - addressing the issues in foot care which lead people with diabetes developing foot conditions Funder: Diabetes UK and Great Foundations Closing date: 1 December 2021 Diabetes UK and Great Foundations are inviting proposals addressing the issues which lead to people with diabetes developing ulcers or other diabetes-related foot conditions and these then progressing further. Preventing foot ulcers, amputations and other severe foot complications in people with diabetes is a key priority for the Diabetes Research Steering Group. There is a clear need for innovative approaches to do this, but these need to consider the findings of previous studies and address factors in foot care which may have previously not been subject to research. These include social factors which present significant barriers to care or treatment, the difficulty people with neuropathy have in detecting and adapting to foot conditions and the need for effective and rapid referrals for foot care when it is needed. More Information Versus Arthritis & MSK TRC - accelerating new treatments Funder: NIHR/Versus Arthritis Closing date: 1 December 2021 As part of the UK Musculoskeletal Translational Research Collaboration (MSK TRC) we are launching the second call for research projects focused on mechanistic experimental/translational medicine studies in humans across the areas of prevention, diagnosis or treatment that are aimed at priming the next transitional step. More information NIHR - Research Professorships, round 12 Funder: NIHR Closing date: 1 December 2021 The NIHR Research Professorships aim to fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. The scheme is open to all professions and all Higher Education Institutions (HEI), in partnership with NHS organisations, or other providers of health, public health and/or care services based in England, to nominate health, public health and social care researchers and methodologists with an outstanding research record of clinical and applied health research and its effective translation for improved health. Candidates must demonstrate they are on a steep career trajectory to become a research leader having spent no more than five years at their current level of seniority at the time of application. More information Davos Alzheimer's Collaborative - increasing cognitive assessment rates for older adults Funder: Davos Alzheimer's Collaborative Closing date: 1 December 2021 The Davos Alzheimer ’ s Collaborative (DAC) is funding innovators who can increase cognitive assessment rates for older adults. The proposed approach should aim to increase the percentage of patients age 65+ who are provided with a standardized cognitive assessment in selected health system(s) or implementation site(s). It should indicate which health system(s) or other implementation partner(s) your team plans work with. It can utilize any cognitive assessment solution, technology or tool with clear evidence of efficacy and potential for sustainability. DAC is agnostic on the exact mechanism for cognitive assessment. Teams can develop a novel solution or implement an existing solution. More information Psoriasis Association: Research Grants Funder: Psoriasis Association Closing date: 3 December 2021 The Psoriasis Association will consider applications that have clear relevance to its aim 'to promote and fund research into the causes, nature and care of psoriasis and to publish and disseminate the results of that research'. The Psoriasis Association offers the following: PhD studentships : Supports the training of graduate students leading to the presentation of a PhD Cecil King Memorial Award : For projects where the principal researcher is under 35 years of age, or within the first five consecutive years, at the time of application, of either their first permanent independent academic research post or a named limited-tenured/fixed-term academic research post, obtained in open competition More Information Southampton Academy of Research - training awards Funder: NIHR SoAR Closing date: 14 December 2021 SoAR funding awards 2021/2022 are now open for applications: Internship award - 6 months Transitional award - 12 months Post doctoral award - 6 or 12 months Further information is available by email NIHR - efficiency and mechanism evaluation programme - new commissioned calls Funder: NIHR Closing date: 7 December 2021 The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments. EME is a partnership between the Medical Research Council (MRC) and the NIHR. The EME Programme is accepting stage 1 applications to their commissioned workstream for the following funding opportunities: Mechanisms of action of health interventions Efficacy trials in regenerative medicine Early detection of disease NIHR efficacy and mechanisma evaluation programme - dementia research call Funder: NIHR Closing date: 7 December 2021 This National Institute for Health Research (NIHR) call invites proposals for dementia research to address important health and social care questions. Research could involve any aspect of prevention, diagnosis, treatment, support or care, and related health and social care services. Applications which involve investigators spanning a range of specialties are encouraged and partnership with national charities welcomed. The PHR and HTA programmes are also accepting proposals in this call - see 30 Nov and 5 Jan. More information NIHR NICE rolling call for research studies addressing NICE research recommendations Funder: NIHR Closing date: 7 December 2021 The Efficacy and Mechanism Evaluation Programme is accepting Stage 1 applications for the NICE rolling call for research studies addressing NICE research recommendations. The EME Programme is interested in receiving applications to meet recommendations in research identified in NICE guidance published from 2015 onwards (for the purposes of this call, NICE guidance includes the following: clinical, social care, public health, technology appraisals, interventional procedures and diagnostics). More information NIHR efficacy and mechanism evaluation programme - researcher-led workstream Funder: NIHR Closing date: 7 December 2021 The Efficacy and Mechanism Evaluation (EME) Programme funds ambitious studies evaluating interventions with potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research in the mechanisms of diseases and treatments. EME is a partnership between the Medical Research Council (MRC) and the NIHR. The Efficacy and Mechanism Evaluation (EME) Programme is accepting stage 1 applications to their researcher-led workstream. Applications are sought for research into interventions that are based or used by the NHS and its partners. More information NIHR 21/561 James Lind Alliance Priority Setting Partnerships rolling call (EME programme) Funder: NIHR Closing date: 7 December 2021 The Efficacy and Mechanism Evaluation (EME) Programme is accepting stage 1 applications to this funding opportunity. The programme recognises the importance of the research priorities identified by the James Lind Alliance (JLA) Priority Setting Partnerships (PSP) and are interested in receiving high-quality applications which address them. More information Royal College of Surgeons of England - pump priming grants Funder: Royal College of Surgeons Closing date: 7 December 2021 The Royal College of Surgeons of England is offering a limited number of awards of up to £ 10,000 to newly appointed consultants, senior lecturers and post-doctoral trainees (appointed since 2015) in surgery who are working at hospitals and universities within the UK. The aim of the awards is to give assistance to such surgeons in the early stages of their independent research careers. Awards may be used, amongst other things, for small items of equipment, for consumables or for technical assistance. All applicants must be members or fellows of The Royal College of Surgeons of England. Applicants must be consultants, senior lecturers or post-doctoral trainees (appointed since 2015) working in surgery in the UK. More information CRUK: Early Detection and Diagnosis Project Award Funder: CRUK Closing date: 8 December 2021 Early Detection and Diagnosis Project Awards fund science to drive transformational change in how and when early cancers and pre-cancerous states are diagnosed. Early detection and diagnosis (ED&D) research seeks to detect and diagnose consequential precancerous changes and cancer at the earliest possible point at which an intervention might be made, reducing the burden of late-stage disease. ED&D projects will support discovery and translational/clinical research which is mindful of the clinical and population context. More Information NIHR i4i - product development awards, call 23 Funder: NIHR i4i Closing date: 8 December 2021 The NIHR Invention for Innovation (i4i) Programme supports the preclinical and clinical development of medical technologies in areas of existing or emerging patient need. The i4i programme invites proposals to Call 23 of its researcher-led Product Development Awards (PDA). PDAs fund the development of disruptive early-stage medical technologies that address existing or emerging healthcare needs. They support translational projects developing medical devices, in vitro diagnostics and digital health technologies that are patient-focused and for ultimate NHS use. More information Wessex REACH - peer support funding Funder: Wessex REACH Closing date: 10 December 2021 A small amount of funding is available to groups of researchers who wish to create a space for thinking, connecting and problem solving with their peers. Anyone currently working in healthcare, social care or in healthcare-related research in Wessex is eligible. Groups can apply for up to £ 500 to be used over a 1 year period. Send a short summary (up to 500 words) detailing your group, reasons for applying, planned activities, objectives and how they align with building research capacity in Wessex, and budget to info@wessexreach.org.uk . For more detail, contact Beth Stuart . More information THIS Institute environmental sustainability fellowship Funder: The Healthcare Improvement Studies (THIS) Institute Closing date: 15 December 2021 Fellowships to enable individuals to conduct research that will help the NHS increase its capacity to improve environmental sustainability. Focus areas in scope could include energy use, waste disposal, procurement and supply chains, operational processes, transport, hygiene practices, equipment and technology, care processes, device or building design, as well as many other research questions relevant to improving sustainability. Findings should be generalisable or transferable and should contribute to scholarly work as well providing real actions that can be implemented. More information CRUK: Prevention and Population Research Project Awards Funder: CRUK Closing date: 15 December 2021 Prevention and Population Research Awards provide support for focused research proposals centred on key questions in prevention and population research. More Information Closing the Gap collaboration fund Funder: UKRI Closing the Gap Network Closing date: 20 December 2021 Funding to support and encourage new and emerging collaborations in the area of severe mental ill health to develop new research proposals that could be funded through the Closing the Gap Network Plus funds or through other funding bodies. More information Action for A-T - research grants Funder: Action for A-T Closing date: 3 January 2022 Action for A-T funds medical research to speed up the process of identifying a cure for Ataxia Telangiectasia (A-T) or treatments that delay or prevent the disabling effects of this devastating childhood condition. Applications are invited for high quality research projects that have the potential to lead to treatments and cures for Ataxia-Telangiectasia. More information NIHR Health Technology Assessment Programme Researcher-led workstream Funder: NIHR Closing date: 5 January 2022 The Health Technology Assessment Programme is accepting stage 1 applications to their researcher-led evidence synthesis workstream, 21/554. More Information NIHR Health Technology Assessment Programme Researcher-led workstream Funder: NIHR Closing date: 5 January 2022 The Health Technology Assessment Programme is accepting stage 1 applications to their researcher-led workstream, 21/555. More Information NIHR 21/558 NIHR James Lind Alliance Priority Setting Partnerships rolling call (HTA Programme) Funder: NIHR Closing date: 5 January 2022 The Health Technology Assessment (HTA) Programme is accepting stage one applications to this funding opportunity. The programme recognises the importance of the research priorities identified by the James Lind Alliance (JLA) Priority Setting Partnerships (PSP) and are interested in receiving high-quality applications which address them. More Information NIHR 21/559 Dementia research call - Health Technology Assessment (HTA) Programme Funder: NIHR Closing date: 5 January 2022 The Health Technology Assessment (HTA) Programme is accepting stage one applications to this funding opportunity. Dementia is a growing challenge that has become one of the most important health and social care issues facing the world. We need to continue building the evidence base, to improve the lives of people affected by dementia. More Information NIHR Policy Research Programme - evaluation of new funding for inpatient detoxification beds Funder: NIHR Closing date: 6 January 2022 The NIHR funds policy research to enable evidence informed policy making in health and social care. The PRP Programme invites applications for a single research project to qualitatively evaluate an initiative to increase provision of inpatient detoxification to improve drug recovery. It is expected this will be based on in-depth interviews with about 30 inpatients and 30 healthcare professionals with initial contact needed in October-December 2021, a follow-up directly after the detox and a further follow-up after 6 months. The project will complement a quantitative analysis being carried out by Public Health England (PHE). More information NIHR James Lind Alliance Priority Setting Partnerships rolling call (HS&DR programme) Funder: NIHR Closing date: 11 January 2022 The Health Services and Delivery Research (HS&DR) Programme is accepting stage one applications to this funding opportunity. The programme recognises the importance of the research priorities identified by the James Lind Alliance (JLA) Priority Setting Partnerships (PSP) and are interested in receiving high-quality applications which address them and are within the scope of the programme. The JLA Priority Setting Partnerships facilitate patients, carers and clinicians to work collaboratively to identify research priorities in particular areas of health and care. Their aim is to ensure that health research funders are aware of the issues that are important to the people who need to use the research in their daily lives. The NIHR research programmes fund research across the National Health Service (NHS), public health and social care to meet the needs of those who plan, provide and receive care and services. The programmes recognise the importance of the research priorities identified by the James Lind Alliance Priority Setting Partnerships and are interested in receiving high-quality applications which address them. More information NIHR Health Services and Delivery Research Programme (standard researcher-led) Funder: NIHR Closing date: 11 January 2022 The Health Services and Delivery Research (HS&DR) Programme aims to produce rigorous and relevant evidence to improve the quality, accessibility and organisation of health and social care services. The HS&DR Programme is accepting stage 1 applications to their researcher-led workstream. The researcher-led workstream welcomes Stage 1 proposals on topics or research questions identified by researchers within the programme ’ s remit. The aim is to fund research that will lead to improvements in health services that will be of greatest benefit to the NHS and to patients. We are interested in a range of types of research including primary research and evidence synthesis. More information NIHR Invention for Innovation - challenge awards, call 13 Funder: NIHR Closing date: 12 January 2022 The Challenge Awards will fund investigations of MedTech innovations in healthcare settings. The aim is to shorten the evidence gap between the safety/efficacy typical of a newly or nearly CE-marked technology and what is required for decisions by commissioners and regulators. At the same time, this will de-risk the product for follow-on investment. Please note that nearly CE-marked technologies refers to technologies that are currently under Notified Body assessment, whereby all of the mandatory testing has been completed. More information Medical Research Foundation - adolescent dermatology Funder: Medical Research Foundation Closing date: 12 January 2022 The aim of this grant is to increase understanding of the disease mechanisms underpinning skin disorders of relevance to adolescents, and improve diagnosis, treatment and management of these diseases. MRF are inviting applications from clinicians who have the potential to be the research leaders of the future, to support research that will increase understanding of the disease mechanisms underlying adolescent skin disorders. Researchers whose work may lead to better understanding of prevention, treatment or management of these disorders are welcome to apply. More information NIHR Programme Development Grants - competition 32 Funder: NIHR Closing date: 13 January 2022 NIHR Programme Development Grants (PDG) are designed to enable a research team to carry out targeted preparatory work to develop a competitive Programme Grants for Applied Research (PGfAR) funding application. They can also be used to further develop an existing or ongoing PGfAR-funded programme of research. Programme Development Grants are designed to increase the rate and number of successful applications for a full Programme Grant by supporting the completion of the necessary preparatory work to suitably position the research team to submit a competitive Programme Grant application. Applications to PDG are made with the support of an NHS body and other providers of NHS services in England. If an application is successful, a contract will be placed with that organisation for delivery of the research and all funds for the research will be paid to the NHS organisation or other provider of NHS services. more information NIHR Population Health Career Scientist Award Funder: NIHR Closing date: 13 January 2022 The NIHR has launched the Population Health Career Scientist Award (PHCSA), a UK-wide initiative to enable senior researchers to make the next step to Reader/Professor level in their host institutions. The PHCSA forms part of a series of initiatives and investments by NIHR to enable local government to become more research active. This new award will help answer the most important research questions facing decision-makers at local and national levels to improve health and reduce inequalities. There is a desire to attract applicants representing the wide range of disciplines which undertake research in areas which impact the determinants of health (e.g. environmental science, mathematics, architecture, engineering, geography, education, social sciences, social policy, arts). More information NIHR Advanced Fellowship Funder: NIHR Closing date: 13 January 2022 The NIHR Advanced Fellowship funds post-doctoral individuals from a range of health and social care professions who have not yet been awarded a chair. Whether you are someone who has recently been or about to be awarded a PhD, or someone with several years of post-doctoral experience, you could be eligible to apply for an Advanced Fellowship. The Fellowship funds: full salary support, including protected time to concentrate on research research costs a bespoke training and development programme to meet individual needs Applicants who are active clinicians or social workers can request for up to 40% of their time to be dedicated to clinical service/development/practice, which will be covered by the Fellowship. We are particularly welcoming applications from researchers looking to undertake research in: Multiple Long Term Conditions – Multimorbidity (MLTC-M) Dementia More Information Royal Institute for Deaf People - fellowships Funder: RNID Closing date: 13 January 2022 The RNID Fellowship scheme aims to build research capacity in hearing research, by supporting the career development of the UK ’ s most talented new ‘ investigators ’ towards becoming independent scientists. Applications are invited in any of the following areas: Research to underpin the development of treatments for hearing disorders, including tinnitus . Including, but not limited to, medical devices, pharmacological treatments, genetic or cellular therapies – treatments should aim to prevent hearing loss, restore auditory function or silence tinnitus. Research to improve how new treatments for hearing disorders, including tinnitus, are developed and tested . Including research to improve the measurement of auditory function or tinnitus, or to develop models of human hearing disorders, including tinnitus. More information Cancer Research UK drug development project Funder: CRUK Closing date: 14 January 2022 Drug Development Projects are not grant funding awards. The funding is there to develop new cancer treatments from preclinical development through to early phase patient trials. Applicants must have a novel cancer agent needing preclinical and/or clinical development and have supporting in vivo efficacy data. All technology areas are considered, including small molecule, biological and other therapeutics. More information NIHR Doctoral Fellowships - round 7 Funder: NIHR Closing date: 18 January 2022 NIHR Doctoral Fellowships provide funding for individuals to undertake a PhD in an area of NIHR research. As part of the creation of the NIHR Academy, four broad Strategic Themes have been identified which represent key priority areas for the NIHR Academy. Applications received under these Themes will still have to meet the same quality threshold required for funding, but will be given priority if the number of fundable applications exceeds the maximum that can be funded. The Themes are: social care, public health, mental health and health data science. More information Parkinson's UK / Rosetree Trust joint senior research fellowship Funder: Parkinson's UK & Rosetree Trust Closing date: 19 January 2022 Parkinson's UK and Rosetrees Trust are jointly funding the Joint Senior Research Fellowship to support early career researchers with an excellent track record in novel cell culture techniques to establish a highly innovative independent drug discovery programme and become research leaders of the future. With this fellowship scheme, the funders are keen to support the progression of neuroprotective treatments for Parkinson's through the development and use of novel cell culture platforms. More information British Heart Foundation - clinical study grants Funder: British Heart Foundation Closing date: *various* see below For clinical trials and observational studies of specific patient groups, usually costing more than £ 350,000 or lasting more than 3 years. The Clinical Study Grant supports funding for: Interventional clinical trials: trials of specific interventions or pathways of care for the prevention, diagnosis and treatment of cardiovascular disease. Interventions include drugs, surgery, devices, psychological, physical and educational interventions. Observational studies of specific patient groups that are hypothesis led and address a defined clinical question(s) over a fixed timescale (up to 5 years). The population of interest should be a patient population, who will usually be recruited within the NHS. The study should have a predefined outcome(s) that will lead to changes in clinical management directly or will inform the development of a clinical trial to test an intervention. Clinical studies can include a mechanistic evaluation, either as a substudy within a clinical trial or as part of an observational study. Closing dates for proposals: 19 January 2022, 11 May 2022 More information British Heart Foundation - consultant research awards Funder: BHF Closing date: 19 January 2022 This new scheme aims to provide protected time to clinically active consultants to undertake substantial cardiovascular research activities in addition to their clinical roles. They provide up to 2 years full-time equivalent of salary support for the primary applicant, to backfill an equivalent number of NHS PAs. This grant can be taken on a full-time basis or spread across up to 5 years, and additional support costs be also be applied for in each year of an award. There will be two fixed calls for this scheme each year. More information Royal Commission for the Exhibition of 1851 - research fellowships Funder: Royal Commission 1851 Closing date: 19 January 2022 The Royal Commission for the Exhibition of 1851 awards Fellowships for advanced study and research in science, engineering, the built environment and design. 1851 Research Fellowships are intended to give early career scientists or engineers of exceptional promise the opportunity to conduct a research project of their own instigation; an ultimate objective is to contribute to the knowledge base required for a healthy and innovative national culture. Around eight awards are made each year. More information Alzheimer's Research UK - senior research fellowship Funder: Alzheimer's Research UK Closing date: 21 January 2022 Senior Research Fellowships are designed to retain excellent clinical and non-clinical researchers who have a track record of nationally competitive research, and clear plans to manage their own independent research group and become internationally recognised within the field of biomedical dementia research. The purpose of Senior Research Fellowships is to foster both clinical and non-clinical researchers in their “ transition to independence ” . Prospective applicants should a have a strong track record of original and productive research in their area (as evidenced by senior author publication(s) or other equivalent outputs), which shows productivity and impact across past appointments (typically at least one previous post-doctoral appointment). More information Alzheimer's Research UK - major projects Funder: Alzheimer's Research UK Closing date: 21 January 2022 Alzheimer ’ s Research UK is a research charity dedicated to causes, diagnosis, prevention, treatment and cure of Alzheimer ’ s. ARUK work across four key areas of action: Understand the diseases that cause dementia; diagnose people earlier and more accurately; reduce risk, backed by the latest evidence; treat dementia effectively. The Major project grant scheme provides funds for high quality research projects. It is provided to cover salaries (research, technical, students etc), equipment, animal costs and running costs (consumables, travel etc). More information NIHR Health Services & Delivery Research Programme - improving choice, access and uptake of contraception Funder: NIHR Closing date: 21 January 2022 The Health Services and Delivery Research (HS&DR) Programme aims to produce rigorous and relevant evidence to improve the quality, accessibility and organisation of health and social care services. The HS&DR Programme is interested in receiving applications to understand the impact of the pandemic on women ’ s, including transgender and non-binary people ’ s, choices, access and their attitudes and preferences towards contraception, especially towards long-acting reversible contraceptives. It is also important to understand their experiences of initial access to contraception in both general practice and sexual and reproductive health services. We are also interested in research that explores women ’ s, including transgender and non-binary people ’ s, experiences of using these services, and the extent to which their care is fragmented or well-coordinated, and what this indicates in terms of how service provision may need to change to meet future needs. Research into understanding experiences of these services in the context of rapid changes to services from face-to-face to remote during the COVID-19 pandemic is also of interest. More information Paget's Association - research grants Funder: Paget's Association Closing date: 25 January 2022 The Paget's Association is a national UK charity providing information and support to all those affected by Paget ’ s Disease of Bone. The Association funds quality research, raises awareness and supports professionals to achieve excellence in care and research. The Paget ’ s Association invites applications for Research Project Grants in all areas of Paget ’ s Disease of Bone. Collaborative research is strongly encouraged, including through our Paget ’ s Association Centres of Excellence (PACEs). More information UHS R&D small grants scheme 2021 Funder: University Hospital Southampton R&D Closing date: 26 January 2022 Grant applications are invited from investigators across the Southampton Partnership for research funding proposals that align with research portfolios within UHS clinical divisions, and/or the UHS/UoS research infrastructure. Up to £ 50k is available for projects up to three years in duration. The application form is available here . Southampton Hospitals Charity - research funding scheme Funder: Southampton Hospitals Charity Closing date: 26 January 2022 Southampton Hospitals Charity (SHC) has partnered with the Research & Development team to fund innovative research projects with the potential to demonstrate direct benefit to UHS patients. The total number of projects awarded will be determined by quality and impact. An exceptionally strong case for funding should be presented for any project costing over £ 50k. Fundraising will launch once the successful projects have been selected and projects are therefore not expected to commence until 9-12 months after award confirmation i.e., not before January 2023. All research designs, disciplines, and scope, except for basic science projects, will be considered. SHC has identified a number of research areas for this round, based on the potential for timely fundraising: cancer care cardiology child health, including neonatal neurology ophthalmology The application form is available here More information NIHR i4i - dementia: digital approaches for early detection, diagnosis and stratification Funder: NIHR Closing date: 26 January 2022 The NIHR Invention for Innovation (i4i) Programme is inviting applications for a Dementia specific funding stream aimed at the research and development of digital approaches for the early detection, diagnosis and stratification of individuals with dementia. The i4i Programme supports the research and development of innovative medical technologies that have demonstrated proof-of-concept and have a clear developmental pathway towards new products for ultimate NHS use. More information MRC Neurosciences and Mental Health - funding opportunity Funder: MRC Closing date: 26 January 2022 Apply for funding for research projects focused on neurosciences and mental health. The MRC Neurosciences and Mental Health Board funds research in neurosciences, mental health and disorders of the human nervous system. The aim is to transform understanding of the physiology and behaviour of the human nervous system throughout the life course in health and in illness, as well as how to treat and prevent disorders of the brain. The research supported by UKRI includes the interactions between the nervous system and other parts of the body, the brain, mental health and physical health. They are also interested in how episodes throughout life impact on lifelong mental and neurological health. More information Leukaemia UK - John Goldman Fellowships Funder: Leukaemia UK Closing date: 31 January 2022 Leukaemia UK John Goldman Fellowships are aimed at early career researchers with a passion for science, a desire to develop new ideas and translate scientific advances into clinical practice. Successful applicants will demonstrate that they are the potential scientific/clinical leaders of the future. Their proposed research project must be novel with the capacity to make advances in our knowledge of leukaemia and related diseases and the development of new and kinder treatments. Applications are accepted from scientists and clinician-scientists working in UK universities, research institutions or hospitals. More information Pancreatic Cancer UK - joint funded clinical research fellowship Funder: Pancreatic Cancer UK & Association of Surgeons of GB and Ireland Closing date: 31 January 2022 The Association of Surgeons of Great Britain and Ireland (ASGBI) and Pancreatic Cancer UK Fellowship: Supports a Trainee or Junior Consultant (within 5 years of first appointment) with an interest in advancing the clinical management of pancreatic cancer. This individual will visit centres of excellence abroad and bring this experience back to the NHS to advance our clinical expertise within the UK. More information British Scoliosis Research Foundation - research grants Funder: BSRF Closing date: 31 January 2022 The British Scoliosis Research Foundation (BSRF) promotes research into the treatment of scoliosis in the UK. Each year the BSRF funds a great deal of research into scoliosis and periodically holds an international symposium to spread the knowledge gained from research. BSRF Research Grants are open to appropriately qualified professionals such as scientists, clinicians, and allied health professionals (nurses, psychologists or physiotherapists). All applications will be considered, however, applicants are advised to submit their proposal under one of the following three headings: Small exploratory grant New investigation grant Major research grant More information British Infection Association - project grants Funder: British Infection Association Closing date: 31 January 2022 The BIA aims to foster excellence in all aspects of clinical infection-related research by supporting patient-facing researchers-in-training to achieve high-quality clinical and basic research in the field of infection. BIA Project Grants provide consumables costs for trainees undertaking an infection-related research project in an academic centre in the UK or Ireland. It is envisaged funds would be used to support preliminary study in a field with intention of developing the work either through a research fellowship or as an independent investigator. More information The Urology Foundation - innovation and research grant Funder: The Urology Foundation Closing date: 31 January 2022 The Urology Foundation (TUF) is dedicated to beating all urology diseases through cutting-edge research and leading education and training to ensure that fewer lives will be devastated. The Urology Foundation (TUF) will fund projects up to a value of £ 60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods. Please note that innovation is necessary but not sufficient for a successful application. For example, a project with innovative methodology would need to lead to a practical end point and similarly, a project aiming to design an innovative treatment would need to have a practical methodology. More information Daphne Jackson Trust and the Kennedy Trust for Rheumatology Research - rheumatology fellowship Funder: Daphne Jackson Trust & Kennedy Trust for Rheumatology Research Closing date: 31 January 2022 Applications are invited for a Kennedy Trust sponsored three year Daphne Jackson Fellowship to be held at any UK university or research establishment. The Fellowship is intended for a scientist wishing to return to research into any clinical or pre-clinical subject in the field of rheumatology and related musculoskeletal or immunological diseases More information Diabetes UK Harry Keen intermediate clinical fellowship Funder: Diabetes UK Closing date: January 2022 The Diabetes UK Harry Keen Intermediate Clinical Fellowship allows outstanding medically qualified professionals and other clinically qualified professionals – including nurses, pharmacists and members of the Allied Health Professions, who have gained a PhD or equivalent (e.g. MD (Res)) – to establish themselves as independent researchers with a view to a long-term career as a clinical research leader in the field of diabetes. It is expected that the app
Url: /ClinicalResearchinSouthampton/For-researchers/Grant-funding-support/Current-funding-calls/Current-funding-calls.aspx

UHS register of interests June 2025

Description: Employee Name Aarvold, Dr Alice Beatrice Rachel Aarvold, Dr Alice Beatrice Rachel Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Adam, Dr Robert Dhugald (Rob) Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Afzal, Dr Nadeem Ahmad Akerman, Dr Catherine Mary Elizabeth Akerman, Dr Catherine Mary Elizabeth Akerman, Dr Henry (Harry) Akerman, Dr Henry (Harry) Akerman, Dr Henry (Harry) Al Rawi, Dr Samar Othman Abed Al Baki (Samar) Al Rawi, Dr Samar Othman Abed Al Baki (Samar) Al Rawi, Dr Samar Othman Abed Al Baki (Samar) Al Rawi, Dr Samar Othman Abed Al Baki (Samar) Al Rawi, Dr Samar Othman Abed Al Baki (Samar) Al-Azzawi, Dr Omar Muataz Shnasi Alderton, Dr Mark Vernon Alderton, Dr Mark Vernon Alderton, Dr Mark Vernon Allan, Dr Charlotte Georgina Allan, Dr Charlotte Georgina Allen, Dr David Charles Allen, Dr David Charles Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Amerasinghe, Ms. Nishani Anderson, Mr. David Frederick Anderson, Mr. David Frederick Anderson, Mr. David Frederick Anderson, Mr. David Frederick Role Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Consultant Interest Declared Y Y Interest Category Financial interests Financial interests Y Financial interests Y Financial interests Y Indirect interests Y Indirect interests Y Indirect interests Y Indirect interests Y Indirect interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Y Financial interests Interest Situation Clinical private practice Clinical private practice Outside employment Outside employment Hospitality Outside employment Outside employment Outside employment Sponsored events Clinical private practice Clinical private practice Clinical private practice Clinical private practice Donations Sponsored events Sponsored events Sponsored events Sponsored research Y Financial interests Sponsored research Y Financial interests Sponsored research Y Indirect interests Clinical private practice Shareholdings and other Y Indirect interests ownership interests Y Financial interests Clinical private practice Shareholdings and other Y Financial interests ownership interests Shareholdings and other Y Financial interests ownership interests Y Financial interests Clinical private practice Y Financial interests Clinical private practice Y Financial interests Clinical private practice Y Financial interests Clinical private practice Y Indirect interests Clinical private practice Shareholdings and other Y Financial interests ownership interests Y Indirect interests Clinical private practice Non-financial Y professional interest Outside employment Non-financial Y professional interest Outside employment Non-financial personal Y interests Loyalty interests Y Y Financial interests Clinical private practice Y Indirect interests Donations Y Financial interests Clinical private practice Y Financial interests Clinical private practice Y Financial interests Donations Y Financial interests Hospitality Y Financial interests Hospitality Y Financial interests Hospitality Shareholdings and other Y Financial interests ownership interests Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored events Y Financial interests Sponsored research Non-financial personal Y interests Sponsored events Non-financial Y professional interest Hospitality Non-financial Y professional interest Outside employment Non-financial Y professional interest Sponsored events Non-financial Y professional interest Sponsored research Y Financial interests Outside employment Y Financial interests Clinical private practice Y Financial interests Sponsored events Y Financial interests Sponsored events Interest Description I have a private orthopaedic list once per month. I have a private list once a month . - Attended a educational event at the Abbott research facility in Sylmar, California, USA. - All travel cost, accomidation and meals were provided for by Abbott. - During the trip I provided 2.5 hours of feedback on future product development which I recieved a consultation fee for. In September 2022 I was part of the expert panel at the New Evidence based approach to Implementing the Four Pillars of HFrEF training event and I received HCP honorarium fees of £250 from AstraZeneca to participating in the event. On the 15th of November 2022 I attended a dinner/update event at the Harbour Hotel in Southampton that was sponsored by Medtronic LTD. I recieved a consultancy fee from AstraZenaza for speaking of cardiovscualar risk in COPD. I recieved a speakers fee from Astra Zeneca for apprearing at a Cardiometabolic GP Symposium. I recieved a speakers fee from Zoll for giving a presentation at EHRA. In September 2023 I attended a CRT training course in Denmark which was funded by Merit Medical. CANDOVER CLINIC BASINGSTOKE I do private work at Candover clinic, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke RG24 9NA I have a private practice at Candover Clinic in Basingstoke and Spire Southampton. However, my practice at Spire Southampton is minimal, as it was intended for private endoscopies, which have not been possible due to a lack of support from the Spire hospital team. I practice at the Candover Basingstoke and the Spire A sum of 9,750 £ received from Dana Fry, a parent for purchase of a Paediatric Fibroscan probe. This is to be used for NHS practice. The moneys were deposited in Charity fund I sought sponsorship from Nutricia to organise a regional Wessex Gastroenterology meeting. The aim of this meeting is to maintain effective regional communication, discuss guidelines and standards of practice, and include presentations with key learning points for our day-to-day work. Comments This does not impact on my NHS work This is a regular list that has no impact on my NHS practice. - The trip was approved by to my line manager. - Merit funded all travel, accommodation and hospitality cost Private practice outside working hours for UHS I see patients with paediatric gastroenterology conditions in the clinic The fibroscan probe will be exceptionally useful for managing and treating children with liver fibrosis CoI Date From CoI Date To 16/09/2024 25/07/2022 25/07/2023 20/07/2022 24/09/2022 21/09/2022 21/09/2022 15/11/2022 15/11/2023 12/09/2024 12/09/2024 22/05/2024 22/05/2024 30/03/2025 30/03/2025 16/09/2023 18/09/2023 01/05/2021 04/10/2022 01/05/2021 01/12/2023 18/10/2024 01/12/2022 19/11/2021 27/02/2024 27/02/2024 Talk on national symposium sponsored by Falk, UK. However I haven't received any moneys yet. I declared my conflict of interest at the talk and the sponsorship didn't influence the content of my talk. WESSEX PAEDIATRIC GI NETWORK MEETING CI for The ACTIVE-IBD Study RHM CHI1102 Awarded 400£ for the study by CICRA - Childhood Crohns Research Association PAID TO PROVIDE LUNCH AND TEA FOR DELEGATES ATTENDING MEETING THE NETWORK MEETING IS FOR TEACHING AND DISCUSSION OF NETWORK PROTOCOLS - THIS TIME WE ARE DISCUSSING MANAGEMENT OF GI BLEEDING IN CHILDREN Ethics REC - Sep 2021 Study started - Nov 2021 35/50 recruited into study 19/10/2023 18/10/2022 18/10/2022 01/02/2022 EnablExercise in Crohns: A qualitativE study to uNderstAnd the Barriers and faciLitators to physical activity and Exercise IN children and adolescents with CROHN’S disease – perceptions of patients, caregivers and clinicians The aim of this project is to understand the barriers to and facilitators of physical activity and exercise training in children and adolescents with Crohn’s disease – incorporating the views of young people with Chrohns, their parents/guardians and doctors. Awarded 25K by GUTS UK (national bidding) Principal applicant DR Zoe Saynor - i m co-applicant SPONSORED RESEARCH My husband works as an anaesthetist in private practice moneys not awarded yet still to commence Granted 25K from GUTS UK to conduct research on Crohns in children with IBD 01/02/2022 01/11/2021 04/10/2022 30/11/2023 My husband has developed an app that allocates staff to vacancies in healthcare. Private healthcare providers are using this currently. I undertake private practice in my own at all the local private hospitals I have shares in Zelemiq Life Science Limited which is a local electronics company that helps other companies navigate through regulatory pathways. They also are creating the Ripple- a non invasive continuous glucose and lactate monitor I part own Alloc8tor that is a company linking together healthcare professionals with available outside work. We currently do no business with UHS or with the NHS. We have a contact with the Nuffield Hospital chain nationally and some other smaller contacts with other private hospitals. We have no plans to sell the company currently 30/11/2023 20/01/2022 01/01/2030 18/02/2024 26/02/2030 20/01/2022 01/04/2025 I am a member of SAS partnership and as such provide anaesthesia services locally. I work with a few surgeons closely and may pick up some as hoc sessions when offered to the group 04/01/2022 04/01/2023 I am part of SAS LLP which includes many colleagues from my trust. We provide anaesthetic services individually and as a group to local surgeons as well as other local providers such as ECT for the RSH. 04/11/2024 I have practicing privileges at both the Nuffield and Spire hospitals. In the past this included choose and book NHS patients but more recently the large majority is insured or self funding. Practicing privileges at both the Nuffield and Spire hospitals I continue to work in local private sectors and will occasionally have UHS outsourced patients on some of my lists 01/12/2020 31/12/2021 01/01/2022 01/01/2023 01/01/2023 31/12/2023 I am the sole shareholder and director of two companies. The first one is Al-Azzawi Trading Limited (Company number 13862060), which is an E-Commerce company that trades medical items such as stethoscopes, ophthalmoscopes, and consumer ECG monitors, as well as non-medical items. The suppliers are exclusively dealt with through eBay, Aliexpress, and Alibaba, while buyers are sold to through I would like to state that this is a declaration of interest rather than a declaration of conflict of interest. None of the time spent directing eBay. The second company is Al-Azzawi Businesses Limited (Company number 13829506), which is a property investment company in the form of Buy-To-Let. either of the two companies is part of my contracted time with the trust, nor does it happen on the trust premises. 28/03/2022 I have worked within the joint NHS/Private Palforzia peanut immunotherapy clinic. This is joint with Southampton NHS Trust however the immunotherapy is not offered via NHS services and it was felt best option to be able to offer this to some of our patients within the region. It does not impact on NHS duties running on a weekend and my role is very much supporting the service rather than leading it. I have not really worked in the service this year and will only support if staff sickness 18/01/2024 Designated doctor for child deaths for Hampshire, isle of Wight, Portsmouth and Southampton. Employed via HIOW ICS Potential COI but likely impact more for HIOW ICB 11/02/2020 NHSE SE Long COVID CYP lead No real conflict of interest to the hospital here 18/01/2024 Married to Mr Edward Gardner Consultant Orthopaedic Surgeon at UHS Asked to declare this at previous appraisals I undertake private clinical practice in Clinical Neurophysiology at the Sarum Road (Circle) Hospital Winchester I run one or two clinics per week, lasting 3 hrs each. We previously completed in a sponsored running event and raised money for the Smile for Wessex (Neuro) charity, which donated a few thousand pounds. We are currently potential beneficiaries of the Smile for Wessex charity, with regards to them funding equipment for a second VT bed. Continued work at Wessex Nuffield and Southampton Spire Also ad hoc work at Prema Clinic Portsmouth Do private practice at Southampton Spire and Nuffield wessex and Prema Laservision Educational Grant from Thea Pharmaceuticals £500 Attended list at Western Eye to watch Miniject insertion Moorfields international Glaucoma meeting - delegate iStent meeting - lecture given Hotel room booked by iStar Registration, dinner and hotel room for one night paid by Thea Pharmaceuticals Honorarium from Glaukos 01/11/2008 26/09/2022 26/09/2022 01/01/2010 12/03/2024 03/10/2021 12/03/2024 14/01/2024 08/02/2022 25/06/2023 02/11/2023 27/01/2024 15/09/2023 Paid a refundable deposit to buy shares in a new private non NHS hospital, where I hope to carry out private practice work in the future AbbVie Advisory Board Advisory Board on Durstyra Basic Glaucoma Course - organizer and facilitator - Alcon Basic Surgical Glaucoma Course, held at Alcon Education Centre, Barcelona Booth talk and podcast at European Society of Cataract and Refractive Surgeons Conference on Elios Chair and organiser of Corneal & Glaucoma Southern Meeting Sponsered by Thea Pharmaceuticals Chair of Wessex Glaucoma Forum Chair of Wessex Glaucoma Meeting Chaired Nguenity 1.5 meeting Chaired Southern Glaucoma and Corneal Meeting Educational Grant Elios Advisory Board Glaukos Advisory Board Honoria from Alcon for Advanced Glaucoma Surgical Course Hydrus Meeting Chaired Honorarium received Alcon Eye Care Hydrus Workshop Hydrus Workshop Course facilitator and lecturer International Glaucoma Consortium - participant Interview for Ophthalmologist magazine Interview on Gemini Study for the Ophthalmologist magazine Lecture series x 4 lectures in Singapore Speaker Lecture to Singapore Audience "More than meets the Eye" MIGS unplugged interview On advisory board for AbbVie Allergan for intracameral drugs use Preserflo User Group Meeting Chair of meeting Speaker at Cataract and Glaucoma Update meeting Wessex Glaucoma Meeting Real world data study in Glaucoma Honorarium paid by AbbVie Honoria received from AbbVie Advice on novel drug delivery to NHS Travel Hotel and dinners paid Honoria paid Course organizer and facilitator/lecturer Honorarium paid Course sponsored Accommodation, flights paid Honorarium paid by Elios Conference registration paid by Elios Hotel room & Dinner paid by Thea Pharmaceuticals Honoria paid Educational event for Wessex Glaucoma consultants Honoria received from Thea Pharmatceuticals Honoria received from Thea Pharmaceuticals Honorarium paid by Alcon Honorarium paid by Thea including hotel room for one night Educational Grant from Thea Pharmaceuticals to attend WGC Educational Event Honorarium from Elios travel , hotel and dinner paid Honoria paid Payments on 13th and 20th May 2025 Educational event for new technique being introduced to Trust Attended event registration, travel and accommodation covered by Alcon UK Honorarium paid by Alcon Honorarium paid by ICG Honorarium from Sight Sciences Honorarium paid by Sight Sciences Honorarium , flights , accommodation x 2 nights paid by AbbVie Honorarium received from AbbVie Honorarium paid by International Glaucoma Consortium Honorarium paid by Santen Hotel room booked Honoria received from Scope Chaired meeting Honoria received from Santen Educational event Sponsorship of data analysis and research methodology from AbbVie 12/05/2025 23/04/2024 01/12/2022 01/12/2022 08/01/2025 10/01/2025 17/04/2024 19/04/2024 07/09/2024 14/03/2025 14/03/2025 12/10/2022 12/10/2022 25/11/2022 25/11/2022 07/09/2024 08/12/2023 27/06/2023 01/07/2023 09/09/2023 10/04/2025 11/04/2025 23/04/2025 24/04/2025 06/07/2023 20/04/2023 21/04/2023 14/06/2024 31/05/2024 08/09/2023 07/09/2024 04/03/2024 05/03/2024 16/08/2023 02/06/2024 07/02/2022 21/11/2023 17/05/2023 17/05/2023 16/05/2023 16/05/2023 01/10/2022 Sponsorship of Charitable endeavor - Everest in the Alps to raise money for Glaucoma UK Sponsorship gained from ELIOS Vision; Santen UK; Thea Pharmaceuticals; iStar Medical Benefit to NHS - raises profile of Glaucoma 28/02/2023 03/03/2023 Sight Sciences Dinner WGC 2023 28/06/2023 28/06/2023 President-Elect UK & Eire Glaucoma Society Professional body affiliated to Glaucoma UK charity 04/05/2022 Educational event - Hydrus Workshop Registration , travel and accommodation covered by Alcon UK 20/04/2023 21/04/2023 Real world study of glaucoma data with Medisoft and research sponsored (no direct financial payment) by AbbVie Consultancy agreement between DFA and Leica Microsystems 20/04/2022 on-going private practice as detailed in Job Plan Leica Microsystems Visualization Summit October 2022 Southampton Corneal Meeting sponsored by Thea Pharmaceuticals Standard NDA and consultancy agreement for advice and presentation to Leica Microsystems from 2022Evening lecture 05/12/2021 20/04/2022 27/09/2023 24/07/2024 13/10/2022 13/10/2022 23/03/2023 23/03/2023 Anjum, Mr. Syed Neshat Anjum, Mr. Syed Neshat Anjum, Mr. Syed Neshat Ansell, Dr Gillian Lindsay (Gilly) Antonakis, Dr Serafeim Antonakis, Dr Serafeim Antonakis, Dr Serafeim Antonakis, Dr Serafeim Antony, Mrs. Shaibi Armstrong, Mr. Thomas Armstrong, Mr. Thomas Armstrong, Mr. Thomas Armstrong, Mr. Thomas Armstrong, Mr. Thomas Armstrong, Mr. Thomas Arshad, Mr. Ali Ahmed Osman Ali (Ali) Arshad, Mr. Ali Ahmed Osman Ali (Ali) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Ayer, Miss Mavis Grace (Mavis) Baker, Mr. Peter Stuart Balabanidou, Miss Eleni Balabanidou, Miss Eleni Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barker, Dr Ruth Emily Barratt, Mr. James Matthew Bateman, Dr Andrew Rea Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Specialist Nurse Practitioner Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Nurse Manager Y Manager Y Consultant Y Consultant Y Manager Y Manager Y Manager Y Manager Y Manager Y Manager Y Manager Y Manager Y Dietitian Specialist Practitioner Y Consultant Y Financial interests Financial interests Non-financial professional interest Clinical private practice Clinical private practice Clinical private practice Indirect interests Financial interests Loyalty interests Clinical private practice Financial interests Financial interests Clinical private practice Shareholdings and other ownership interests Financial interests Non-financial professional interest Financial interests Financial interests Indirect interests Non-financial personal interests Non-financial personal interests Non-financial professional interest Indirect interests Non-financial professional interest Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Non-financial personal interests Non-financial personal interests Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Sponsored events Hospitality Sponsored events Sponsored events Sponsored events Loyalty interests Sponsored events Clinical private practice Clinical private practice Clinical private practice Hospitality Hospitality Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Outside employment Hospitality Hospitality Hospitality Hospitality Sponsored events Sponsored events Outside employment Financial interests Non-financial personal interests Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Non-financial professional interest Outside employment Loyalty interests Sponsored posts Sponsored posts Sponsored posts Sponsored posts Sponsored posts Sponsored posts Sponsored posts Sponsored posts Indirect interests Financial interests Sponsored events Clinical private practice I have got private practice privilege in Spire Southampton & Wessex Nuffield Hospitals My private practice mirrors NHS practice I do private practice in Spire & Nuffield hospital and my practice mirrors my NHS practice. I am joint owner of a LLP company with my spouse. His private practice income (HealthShare Winchester, Nuffield Hospital, Chandlers Ford) is paid directly into that company. My spouse also works in industry for a small company called OCG (orthopaedic Consulting Group) as a CMO and this income is also paid directly into the LLP. He does 1 day a week in industry and 1/2 day a week private practice. I have private practice privileges at Spire Southampton Hospital I see patients and do private Vitreoretinal and Cataract surgery through self-referral or/and insured work. Overall Time Commitment: Dedicated session on Job plan or weekends. (Information included in my previous portfolio appraisal documents) I perform cataract surgery un the ICS (NHS pathway) with the following providers: - Newmedica (since October 2020) I stopped working with the following providers: - Optegra (November 2020 - July 2022) - SpaMedica (June 2021 - June 2022) Overall time commitment: Dedicated session on job plan for private work or/and weekends with no on-call commitment or/and non-working time of NHS job plan. (already included in my previous portfolio documents) (14-6-2023: updated status) Service Contract Agreement with New Medical Systems Ltd as Shareholder and Joint Venture Partner in Newmedica Solent OJV. (Contract agreement signed - Newmedica Solent OJV will start offering its services from mid-September 2023) Sponsorship by Alimera to attend American Academy of Ophthalmology (virtual) Congress. As it is stated in the agreement document with Alimera, sponsorship does not constitute an inducement to prescribe, recommend, buy or sell any medicine or product. (Agreement document and details of sponsorship already included in my portfolio appraisal documents.) I have attended MS Trust conference from 23/03/2025 to 25/03 /2025 ENETS Honorarium paid by AAA to lecture at UKINETs symposium Ipsen paid for registration, travel and accommodation to ENETs in Vienna sponsored by AAA Committee member for UKINETs IPSEN Funded attendance at ENETS Conference 2022 and honorarium for supporting an educational event I do private practice in the same clinical sphere private practice I undertake clinical private practice at Spire Hospital Southampton Attending meeting for Merck conference Sponsorship to Conference (CMSC) Roche Ad board Sanofi Advisory Board Novartis Advisory board £420 Advisory board ( Roche) Advisory board Biogen CHARMS steering committee 5-7pm £540 Chairing an evening meeting Roche Chairing and speaking at a Biogen symposium at conference Chairing and speaking at an evening meeting/debate. Novartis Chairing national meeting Chairing sponsored symposium Charing evening meeting ( Merck) Evening Steering committee meeting with Novartis Filming for Merck Interview for market research for Roche paid £100 MS Nursing Connections ad board Meeting for an hour at 2pm Merck Advisory Board Merck Steering Committee Merck Steering committee meeting ( evening) Nursing Practice conference speaker Paid speaking engagement at REALMS Paid speaking engagement ( evening meeting with Novartis) Paid speaking engagement at Get Smart ( Novartis) Paid speaking engagement at INFORM MS Recording of podcast with Biogen Roche Steering committee Roche steering committee meeting ( paid) Roche- chairing a national meeting Roche- promotional material consultancy Roche- sponsorship to attend CMSC ( international conference) and chairing meetings Sanofi advisory board Sanofi- roundtable consultancy Speaker at an evening meeting, sponsored by Novartis Speaker conference Speaking at Biogen meeting for Saudi Nurses. Two separate days 45 mins each Speaking at a conference( Roche) Speaking at a conference, Nurse at the Limits Speaking at a meeting for Merck Speaking at a symposium ( Janssen) Speaking at an evening meeting Steering Committee meeting Steering committee 23rd of March and 27th of March £300 Virtual Advisory Board 5-8pm Biogen £452 ongoing commitment 6pm-7pm 2 hour evening meeting Sponsorship to CMSC Sponsorship to ECTRIMs Milan ( biogen) Sanofi- delegation to ECTRIMS international conference Speaker at conference and hospitality Sponsorship to International Conference Unknown amount Sponsorship to International conference unknown amount 01.05.25: Appointment as Director of YMCA Fairthorne Housing Trustee position of a local charity. I do not consider this to create a conflict of interest with my role at UHS Since the 1st of June 2021 I have started working with Practice Plus Group in Southampton as a Consultant. I hold a part time contract with the company of 20hrs a week. I treat NHS patients there as well. It currently keeps my elective operating skills up to date as my SUHT Contract is purely trauma operating. I am married to another Orthopaedic Hand Surgeon who is currently an employee of Practice Plus Group in Southampton Community Manager: Community Manager (a peer-support and forum) for ‘Healthcare Professionals in Research’ group - unpaid role. Early Career Working Group committee chair: Chair of international committee with American Thoracic Society Pulmonary Rehabilitation Assembly - unpaid role. National co-lead: National co-lead for /AHP's Everywhere’ group - unpaid role. Visiting Fellow: Visiting Fellow contract with UoS - unpaid role. Community Manager: Community Manager (a peer-support and forum) for ‘Healthcare Professionals in Research’ group - unpaid role. Early Career Working Group committee chair: Chair of international committee with American Thoracic Society Pulmonary Rehabilitation Assembly - unpaid role. National co-lead: National co-lead for /AHP's Everywhere’ group - unpaid role. Visiting Fellow: Visiting Fellow contract with UoS - unpaid role. Sponsorship of BIMDG conference by Nutricia Metabolics Private Oncology practice conduct at Spire Southampton and Genesis Southampton private clinical practice mirrors NHS practice i.e. Clinical Oncology for GI cancer Is ongoing 09/11/2024 22/06/2022 22/06/2022 22/06/2022 09/01/2020 20/09/2020 28/10/2020 09/06/2023 12/11/2021 13/11/2021 23/03/2025 25/03/2025 12/03/2024 14/03/2024 04/12/2022 04/12/2022 22/03/2023 24/05/2023 05/02/2022 05/03/2035 09/03/2022 11/03/2022 05/02/2022 16/05/2023 01/01/2021 07/02/2022 26/04/2024 26/04/2024 21/04/2023 22/04/2023 27/05/2024 02/06/2024 11/12/2024 11/12/2024 30/11/2022 30/11/2022 12/05/2022 19/06/2024 19/06/2024 01/12/2022 01/12/2022 08/11/2021 09/11/2021 21/11/2024 21/11/2024 26/03/2023 24/01/2023 24/01/2025 25/01/2025 17/09/2022 17/09/2022 03/04/2025 03/04/2025 21/02/2023 13/08/2024 13/08/2024 13/10/2021 13/10/2021 05/02/2025 05/02/2025 22/10/2024 22/10/2024 27/07/2022 27/07/2022 06/09/2022 06/09/2022 27/02/2025 27/02/2025 09/11/2022 09/11/2022 09/06/2023 09/06/2023 28/11/2023 28/11/2023 11/11/2023 11/11/2023 21/09/2023 21/09/2023 07/02/2023 18/04/2023 18/04/2023 03/10/2023 03/10/2023 20/06/2025 21/06/2025 23/04/2025 23/04/2025 26/05/2025 02/06/2025 28/02/2023 23/04/2025 23/04/2025 28/11/2023 28/12/2023 30/09/2022 01/10/2022 04/03/2023 05/03/2023 10/02/2024 10/02/2024 16/11/2024 16/11/2024 13/11/2024 13/11/2024 19/03/2024 19/03/2024 16/10/2024 16/10/2024 03/09/2024 03/09/2024 23/03/2022 25/11/2021 25/11/2021 29/05/2023 03/06/2023 11/10/2023 13/10/2023 23/09/2025 26/09/2025 17/09/2024 20/09/2024 31/05/2022 04/06/2022 31/05/2022 04/06/2022 01/05/2025 01/05/2028 01/06/2021 30/06/2022 06/05/2012 10/11/2021 01/01/2020 01/04/2022 01/07/2022 19/04/2021 01/01/2020 01/04/2022 01/07/2022 19/04/2021 11/06/2024 12/06/2024 01/10/2007 22/11/2024 Bateman, Professor Adrian Calvin Bateman, Professor Adrian Calvin Bates, Dr Andrew Tom Bates, Dr Andrew Tom Bates, Dr Andrew Tom Bates, Dr Andrew Tom Baxter, Dr Mark Alan Beck, Mr. Nicholas Edward Beecham, Mr. Ryan Christopher Beedle, Mr. Matthew Ian (Matt) Belgi, Dr Geeta Belgi, Dr Geeta Berry, Mrs. Lisa Jane Bevan, Ms. Amanda Bhargava, Dr Vidhi (Vidhi) Bhatnagar, Dr Adityanarayan Bhatnagar, Dr Adityanarayan Birch, Mr. Brian Robert Peter Birkett, Mr. Lewis Terence Blackwell, Ms. Nicola (Nicky) Blackwell, Ms. Nicola (Nicky) Blake, Mrs. Sinead Patricia (Sinead) Boswell, Dr Owen David Boulos, Mr. Nabil Adel Aziz Bowley, Mr. Adam Marcus Haydon Boyce, Dr Sara Rosalind (Sara) Boyce, Dr Sara Rosalind (Sara) Boyce, Dr Sara Rosalind (Sara) Boyce, Dr Sara Rosalind (Sara) Brain, Dr Amanda Rachel Brander, Mr. Matt Lee Breen, Dr David John Breen, Dr David John Breen, Dr David John Briant, Mr. Jason Scott (Jase) Broadbent, Miss Bethany (Beth) Broadley, Dr Rachel Jane Broadley, Dr Rachel Jane Bromby, Mr. Mark David Brooks, Mrs. Julie Bryant, Dr Timothy Bryant, Dr Timothy Bryant, Dr Timothy Bryant, Dr Timothy Bujanova, Dr Jana Bull, Mr. Colin Lawrence Bulters, Mr. Diederik Olivier Bulters, Mr. Diederik Olivier Bulters, Mr. Diederik Olivier Burke, Dr Georgina Burke, Dr Georgina Burke, Dr Hannah Burke, Mr. Martin James Burke, Mr. Martin James Burke, Mr. Martin James Butler, Mrs. Eleanor Mary (Eleanor) Byrne, Dr James Patrick Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Analyst Y Manager Y Consultant Y Consultant Y Nurse - Advanced Practitioner Y Pharmacist Y Consultant Y Consultant Y Consultant Y Consultant Y Manager Y Occupational Therapy Specialist Practitioner Y Occupational Therapy Specialist Practitioner Y Specialist Nurse Practitioner Y Consultant Y Pharmacist Y Physiotherapist Specialist Practitioner Y Consultant Y Consultant Y Consultant Y Consultant Y Associate Specialist (Closed to new entrants) Y Manager Y Consultant Y Consultant Y Consultant Y Analyst Y Specialist Healthcare Science Practitioner Y Consultant Y Consultant Y Specialist Healthcare Science Practitioner Y Nurse Manager Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Manager Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Consultant Y Manager Y Manager Y Manager Y Physiotherapist Manager Y Consultant Y Financial interests Financial interests Financial interests Financial interests Financial interests Indirect interests Non-financial professional interest Clinical private practice Loyalty interests Clinical private practice Hospitality Hospitality Loyalty interests Clinical private practice Financial interests Clinical private practice Financial interests Outside employment Non-financial professional interest Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Financial interests Hospitality Clinical private practice Clinical private practice Loyalty interests Sponsored events Clinical private practice Clinical private practice Outside employment Financial interests Non-financial personal interests Sponsored events Gifts Indirect interests Clinical private practice Indirect interests Outside employment Financial interests Indirect interests Outside employment Clinical private practice Non-financial professional interest Sponsored events Financial interests Financial interests Financial interests Financial interests Financial interests Non-financial personal interests Non-financial personal interests Financial interests Financial interests Non-financial professional interest Non-financial personal interests Clinical private practice Outside employment Outside employment Outside employment Sponsored events Outside employment Gifts Sponsored events Sponsored events Sponsored events Gifts Financial interests Financial interests Financial interests Financial interests Non-financial professional interest Financial interests Gifts Outside employment Shareholdings and other ownership interests Clinical private practice Loyalty interests Hospitality Financial interests Financial interests Hospitality Hospitality Financial interests Indirect interests Financial interests Financial interests Financial interests Financial interests Financial interests Non-financial professional interest Financial interests Non-financial personal interests Outside employment Sponsored events Outside employment Clinical private practice Outside employment Outside employment Sponsored events Sponsored events Sponsored events Gifts Non-financial personal interests Hospitality Non-financial personal interests Financial interests Financial interests Hospitality Clinical private practice Outside employment I undertake private practice at the Spire Southampton and Wessex Nuffield Hospitals I am registered with Source Bioscience and Backlogs - which are remote locum companies in cellular pathology I am the Editor in Chief of the journal Diagnostic Histopathology and receive an honorarium for this. Private Practice with admitting rights at UHS, Spire Southampton Hospital and Genesis Care Southampton. 3 hours per week on Wednesday am in Job Plan. Honoraria for talk to Astra Zeneca Sponsored Satellite Symposium at BTOG January 2022. £800 Hospitality from Genesis Care: Dinner Lainston House Hotel 2/12/21 Dinner Ennios Restaurant, Southampton 6/10/22 Mr wife, Claire Walsh (Bates) is a GP Partner at Stockbridge Surgery. Chemotherapy mostly delivered at UHS in Solent Suite. Radiotherapy delivered at UHS and Genesis Care. Most of my Private Practice radiotherapy is now with Genesis Care at Spire Southampton Hospital. Previously most of my Private radiotherapy was delivered at UHS, but the waits are now too long. Patients from Stockbridge Surgery are referred to UHS 05/02/2022 01/09/2024 05/02/2022 01/09/2024 01/06/2006 31/12/2025 27/01/2022 27/01/2022 02/12/2021 06/10/2022 01/01/2010 31/12/2025 I do a weekly private outpatient clinic at Spire/Nuffield. This takes about 4 hours per week This has been ongoing for many years, no change and doesn't impact my NHS practice 25/09/2022 31/03/2023 General and colorectal surgeon including outpatients, endoscopy/colonoscopy, operating. Practicing at: Spire Southampton Hospital, Chalybeate Close, Southampton SO16 6UY Nuffield Health Wessex Hospital, Winchester Road, Chandlers Ford, Eastleigh SO53 2DW Tuesday pm colonoscopy Spire hospital Tuesday evening Outpatients Nuffield hospital (variable/ad hoc surgery) Updated 04.09.24 confirmed private practice as outlined. 01/10/2004 04/09/2024 Looking to be Part Time self employed (weekend work) to be a system analyst for other UK Hospital Sites which use the same software we use in critical care (MetaVision). The skills I have built within my First time filling one of these in so i am happy to reply with more information if needed. I have set the date to a year as i am unsure how the current role within the trust would aide in my Part Time self employment i.e. analysing databases and building reporting solutions I would currently remain as a full time member of UHS. part time self employment will last for in its early stages. 11/05/2023 11/05/2024 Flights, accommodation and conference attendance at the the CPSI (TruBridge) conference in the USA in May 2024. TruBridge are the supplier we partner with to develop My Medical Record. This conference will include an in-person user group (with other TruBridge customers). It will also include meetings with the TruBridge product team, where we will discuss alignment (including potential blockers) of the TruBridge and My Medical Record product roadmaps. I notified my line manger (David Cable) as soon as I received the invite and I also have a approval from Jason Teoh (CIO). I do private work at nuffield. This work is on a wednesday and is documented in the job plan My work at Spire is in NHS hours only. I have private practice to declare I notified my line manger (David Cable) as soon as I received the invite and I also have a approval from Jason Teoh (CIO). I've added this as 'non-financial professional interest' although I'm not sure if that is the correct category? It seemed the best fit from the options. I have private practice to declare. My practice is at the nuffield and Spire hospitals 28/04/2024 03/05/2024 01/06/2022 06/06/2023 01/06/2023 07/06/2024 Advisory Board Member for: DGH Pharma (Europe) Ltd Kemp House 160 City Road London United Kingdom EC1v 2NX Payment received for education session at meeting sponsored by Chiesi. I work for Spire Southampton, Nuffield Wessex hospitals outside of NHS hours. I do remote reporting for Backlogs limited. I work in the private hospital as a consultant oncologist. Private hospitals include Spire Southampton, Genesis radiotherapy, new hall hospital Salisbury. I also undertake private patient work at UHS Southampton Working with GCUK - private radiotherapy provider. Working as a clinical oncologist for approximately 3 to 4 hours a week as MR -Linac specialist. Currently UHS does not have MR Linac therefore there is no direct conflict of interest. have either received research grants, honoraria to speak at, chair and attend meetings or liaised/received educational material from representatives of the following companies over the last 20 years: · Astellas · Pfizer · Ipsen · Glaxo Smith Kline · Sanofi · Lilly · Bayer · Amgen · Ferring · Takeda · Comvita · AstraZenecaJanssen-Cilag · Janssen The latest were from 1. Janssen to attend (as faculty) the prostate cancer summit in the UK (2020) 2. Laborie for providing a presentation to be used at the ICS meeting in Melbourne (20210) (2020) Christmas food box from a supplier - Softcat – of mostly perishable items (crisps, chocolate, cranberry sauce, biscuits, bottle of wine). The market value of the items is estimated at less than £15. Generally thee support provide has been to attend conferences or fund research. I do not hold shares (directly) in any companies providing health care resources of any kind to the NHS or other like companies. I have a Private Practice based at the Wessex Nuffield that might be considered a potential conflict of interest to my work with the NHS and UHS but I manage this along NHS and UHS guidelines and do not perform any procedures there that I do not perform on the NHS other than reversal of vasectomy as this is not generally funded by the NHS. Given the relatively low value, perishable nature, and inconvenience of returning the item to the supplier, it was deemed appropriate for the team to keep this food box. 01/06/2022 31/12/2022 01/04/2021 31/03/2022 20/02/2023 24/03/2025 01/01/2009 31/03/2025 01/04/2024 31/03/2025 07/02/2002 08/07/2022 20/12/2023 20/12/2023 Private OT consultations, on an as and when basis. This is not advertised through verbal or printed advertisements, social media or verbally mentioned, within my current role 27/03/2024 Sole Trade Home/ Mobile Beauty Therapist Case Support/ Brilliant Minds- Epilepsy Teaching (Self Employed) The Grove, North Road Dibden/ Longview, Fryern Court Road Private Epilepsy Awareness and emergency medication training sessions No committed hours/ as and when needed (approx. 4-10 hours per month) Private practice and member of SAS Received sponsorship for flight and hotel accommodation relating to a professional conference in Madrid, Spain. Sponsorship covered only the two days of the conference. Conference details: XLH international conference. Date: 18-19th April 2024. Sponsor: Kyowa Kirin. I prescribe burosumab at UHS, a biological therapy for children with a rare condition (XLH). The therapy is manufactured by Kyowa Kirin. I am an associate of MDT Rehab providing private clinical physiotherapy in an intermittent capacity. 1/ training as AstraZeneca speaker - 19/3/24 £1080 2/talk for AstraZeneca - 16/10/24 £405 Speaker fee- AstraZeneca £500 speaker fee for Sanofi - £760 Advisory board for CSL Behring Sponsorship to attend ISTH congress by Sanofi This is an ongoing Profession before i initially started my first employment at UHS Dec 2008 I will not advertise or provide information about private practice unless specifically asked. If the information is requested I will offer a number of options and not declare which company I am associated with. 17/10/2023 07/06/2022 13/07/2023 14/07/2023 17/04/2024 19/04/2024 01/11/2023 01/01/2024 01/01/2025 21/09/2023 21/09/2023 03/07/2023 03/07/2023 17/01/2023 I have my own business as a sole trader - making and selling dichroic glass jewellery. This is entirely conducted in my own time. Christmas food box from a supplier - Softcat – of mostly perishable items (crisps, chocolate, cranberry sauce, biscuits, bottle of wine). The market value of the items is estimated at less than £15. Proctor and advisory board to Neuwave/Johnson&Johnson. Proctoring for Boston Scientific on image-guided Cryoablation Given the relatively low value, perishable nature, and inconvenience of returning the item to the supplier, it was deemed appropriate for the team to keep this food box. On-site proctoring on image-guided microwave ablation. Payment made to UoS Southampton Charitable fund. Onsite proctoring- payments made to UoS Southampton charitable fund. 04/01/2024 21/12/2023 21/12/2023 07/06/2018 22/06/2022 Advisory panel to Varian/Siemens healthcare systems. Christmas food box from a supplier - Softcat – of mostly perishable items (crisps, chocolate, cranberry sauce, biscuits, bottle of wine). The market value of the items is estimated at less than £15. Technical advice. Usually consulted at conferences. Given the relatively low value, perishable nature, and inconvenience of returning the item to the supplier, it was deemed appropriate for the team to keep this food box. 01/06/2021 22/06/2022 21/12/2023 21/12/2023 One-time receipt of cheque to value of £152 payable to myself from Mortuary Fund. Mortuary fund accrues voluntary donations from various/multiple external bodies (namely funeral directors) to UHS mortuary in recognition of additional assistance provided to these companies by mortuary team outside of their contracted role (e.g. patient handling & chasing paperwork). The total amount donated to the fund in each calendar year is divided equally amongst all mortuary employees annually, with all members of team (9x staff B3-B8a) receiving an equal share. No interests as received from multiple & various different donors on a voluntary basis. No service contracts are in place between UHS mortuary & donors and so no opportunity for influence in decision making. Terema Ltd: provision of teaching for Human Factors training company. Paid daily rate on attendance. No financial stake in business. As above 01/04/2021 31/03/2022 06/02/2022 31/12/2024 Founder of REN Think Ltd Facilitation of education and training in team skills, human factors, leadership; speaker 13/04/2025 30/04/2034 Spire Southampton Hospital Chalybeate Close Southampton SO16 6UY Occasional spinal cord monitoring performed during spinal operations (usually scoliosis correction). 2-3 cases per year. 01/01/2015 Coordinator of the Wessex Branch of the Infection Prevention society Infection Prevention society Blackburn House, Redhouse Road, Seafield, Bathgate, West Lothian, EH4 7AQ BSIR 2022 attenda
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/UHS-register-of-interests-June-2025.pdf

Papers CoG 29.04.2025 v2

Description: Date Time Location Chair Agenda Council of Governors 29/04/2025 14:00 - 15:45 Conference Room, Heartbeat/Microsoft Teams Jenni Douglas-Todd 1 Chair’s Welcome and Opening Comments 14:00 2 Declarations of Interest 14:04 3 Minutes of Previous Meeting 14:05 Approve the minutes of the previous meeting held on 29 January 2025 4 Matters Arising/Summary of Agreed Actions 14:06 5 Strategy, Quality and Performance 5.1 Chief Executive Officer's Performance Report 14:07 Receive and note the report Sponsor: David French, Chief Executive Officer Attendee: Gail Byrne, Chief Nursing Officer 5.2 Annual Report and Quality Accounts Timetable 2024/25 14:27 Note the timetable Sponsor: David French, Chief Executive Officer Attendee: Karen Russell, Council of Governors Business Manager 5.3 Draft Quality Accounts 2024/25 14:32 Review and feedback Sponsor: Gail Byrne, Chief Nursing Officer Attendee: Helena Blake, Head of Clinical Quality Assurance 5.4 Corporate Objectives 14:42 Review and feedback Sponsor: David French, Chief Executive Officer Attendee: Kelly Kent, Head of Strategy and Partnerships 5.5 Non-NHS Activity 14:52 Receive and note the update Sponsor: Ian Howard, Chief Financial Officer Attendee: Pete Baker, Commercial and Enterprise Director 5.6 Break 15:02 6 Governance 6.1 Governor Attendance at Council of Governors' Meetings 15:12 Review governor attendance at Council of Governors' meetings Sponsor: Jenni Douglas-Todd, Trust Chair Attendee: Karen Russell, Council of Governors' Business Manager 6.2 Council of Governors' Elections 2025 15:17 Note the timetable Sponsor: Jenni Douglas-Todd, Trust Chair Attendee: Karen Russell, Council of Governors' Business Manager 6.3 Appointment to the GNC 15:19 Sponsor: Jenni Douglas-Todd, Trust Chair Attendee: Karen Russell, Council of Governors' Business Manager 7 Membership Engagement and Governor Activity 7.1 Membership Engagement 15:21 Receive the report Sponsor: Jenni Douglas-Todd, Trust Chair Attendee: Sam Dolton, Events and Membership Officer 7.2 Governors' Nomination Committee Feedback 15:31 Chair: Jenni Douglas-Todd, Trust Chair 8 Review of Meeting 15:36 Review and feedback on the content of this meeting Sponsor: Jenni Douglas-Todd, Trust Chair 9 Any Other Business 15:41 Raise any relevant or urgent matters that are not on the agenda 10 Date of Next Meeting: 16 July 2025 15:44 Note the date of the next meeting Page 2 Minutes - Council of Governors (CoG) Open Session Date Time Location Chair Present 29 January 2025 14.00-15.30 Conference Room, Heartbeat Education Centre and Microsoft Teams Jenni Douglas-Todd, Trust Chair Jenni Douglas-Todd, Trust Chair Shirley Anderson, Elected, New Forest, Eastleigh and Test Valley Theresa Airiemiokhale, Elected, Southampton City Katherine Barbour, Elected, Southampton City Patricia Crates, Elected, New Forest, Eastleigh and Test Valley Sandra Gidley, Elected, New Forest, Eastleigh and Test Valley Lesley Gilder, Elected, Southampton City Ben Grassby, Elected, Rest of England and Wales Linda Hebdige, Elected, Southampton City Councillor Pam Kenny, Appointed, Southampton City Council Professor Sue Latter, Appointed, University of Southampton Jenny Lawrie, Elected, Southampton City Brian Lovell, Elected, Rest of England and Wales Councillor Louise Parker-Jones, Appointed, Hampshire County Council Cat Rushworth, Elected, Isle of Wight Karen Smith-Baker, Elected, Health Professional and Health Scientist Staff Jake Smokcum, Elected, Nursing and Midwifery Staff Mike Williams, Elected, New Forest, Eastleigh and Test Valley JDT SA TA KB PC SG LG BG LH PK SL JL BL LPJ CR KSB JS MW In attendance Tracey Burt, Minutes TB Sam Dolton, Events and Membership Officer SD David French, Chief Executive Officer (for item 5.1) DF Steve Harris, Chief People Officer (for item 6.1) SHa Craig Machell, Associate Director of Corporate Affairs and CM Company Secretary Karen Russell, Council of Governors’ Business Manager KR Apologies Professor Cathy Barnes, Appointed, Solent University CB Sathish Harinarayanan, Elected, Medical Practitioners and Dental SH Staff Esther O’Sullivan, Elected, New Forest, Eastleigh and Test Valley EO Liz Taylor, Elected, Non-Clinical and Support Staff LT 1 Chair’s Welcome and Opening Comments The Chair welcomed everyone to the meeting and in particular, BG and SL, who were attending their first CoG, although they had attended the strategy day at the end of last year. 1 2 Declarations of Interest There were no new declarations of interest relating to matters on the agenda. 3 Minutes of Previous Meeting The minutes of the meeting held on 23 October 2024 were approved as an accurate record of the meeting. 4 Matters Arising/Summary of Agreed Actions All actions had been completed. 5 Strategy, Quality and Performance 5.1 Chief Executive Officer’s Performance Report The Chair welcomed DAF who joined the meeting to present the performance report. He highlighted the following from the report and commented on various national issues:- • the Trust had been under significant pressure related to urgent and emergency care. Whilst this was also a national problem, attendances at the UHS Emergency Department had been higher than last year, averaging 448 patients a day. During the Christmas period, attendances and admissions had been exacerbated by Covid-19 and flu. Various Trusts had declared critical incidents but UHS had not, although it had been close to doing so. • pressure on the Emergency Department had eased slightly in January but during the last week it had increased again. At midnight on 27 January 2025 there had been 150 patients in the department, which was double the normal capacity. • infection prevention was a greater challenge when the hospital was under intense pressure but the Trust was focussed on it. • the Trust had seen an increase in Never Events. A theme related to invasive procedures and missed opportunities to stop, before procedures had started, had been identified. A plan to mitigate such events had been put in place and the Trust would implement the National Safety Standards for Invasive Procedures (NatSSIPs). • the Trust’s referral to treatment (RTT) waiting list had remained above 60,000 in quarter three. 62% of patients on the waiting list had been waiting less than 18 weeks, which meant that UHS was in the top quartile when compared to peer teaching hospitals. • UHS had delivered elective recovery fund activity (ERF) at 128% of 2019/20 levels, which was 15% above the Trust’s target. • the physical capacity of the UHS estate continued to be a challenge. • the funding mechanism related to how ERF money was paid, continued to be a challenge for the Trust. It was hoped that national planning guidance, due out on 30 January 2025, would provide clarity. • the annual staff survey had now closed and the Trust was beginning to receive initial results. These would be shared in due course. • there had been a slight increase in staff sickness absence, largely due to Covid-19 and flu. • the Trust had a significant financial deficit and needed to get back to breakeven. 2025/26 was likely to be another difficult year and it was known that three national priorities would be safe emergency care, reductions in the elective waiting list and the need for Trusts to live within their means. BL queried whether the Trust had done everything it could, in terms of its financial situation. DAF advised that UHS had recently received productivity benchmarking data, which showed that it was fourth in the country, when compared to others, so the Trust was struggling to see what it could do better. 2 SG queried whether all activity for 2025/26 had been capped. DAF advised that new operations and elective outpatient procedures were presently paid for on a price per unit basis, whilst almost everything else was on a block contract. UHS was generally doing more activity than the block assumed and it was likely that elective activity would also be capped next year. The Trust may, therefore, need to consider pulling back on the things that added the least value. CR noted that people were generally living longer and asked whether that was being considered, from a financial perspective. DAF advised that UHS would always support clinical decisions, regardless of a patient’s age. The Chair thanked DAF for attending CoG. 6 Governance 6.1 Chair and Non-Executive Director Appraisal Process The Chair welcomed SHa to the meeting and noted that as a Foundation Trust, UHS was required to conduct a robust appraisal process. The process started in January and would conclude in April. The governors had a vital role in providing feedback on the work of the Non-Executive Directors (NEDs) and system partners would also be asked to provide feedback on the Chair. The Chair would conduct the NEDs appraisals and Jane Harwood, Senior Independent Director (SID) would undertake the Chair’s appraisal. SHa advised that NHS England was due to launch a new appraisal process, nationally, for NEDs but it was still outstanding. However, a refreshed appraisal process for Chairs had been released in 2024. SA noted that governors often found it difficult to provide feedback on the NEDs and advised that she had some helpful tips to share with them, at the end of the CoG meeting. Decision: The CoG approved the Chair and NED appraisal process for 2024/25. 6.2 Audit and Risk Committee Terms of Reference CM advised that the Audit and Risk Committee had carried out the annual review of its Terms of Reference and two minor amendments had been proposed: • to amend 10.2 to Code of Governance for NHS Provider Trusts. • to remove Charitable Funds Committee from Appendix A. Decision: the CoG supported the proposed changes to the Audit and Risk Committee Terms of Reference. 6.3 Governors’ Nomination Committee Terms of Reference CM advised that the Governors’ Nomination Committee had reviewed its Terms of Reference on the 15 January 2025 and the CoG was asked to approve the removal of the words “deputy chair” from paragraph 3.2. Decision: the CoG approved the proposed, minor change, to paragraph 3.2. 6.4 Council of Governors’ Annual Business Plan 2025/26 KR advised that each year the CoG was required to review its Annual Business Plan for the coming financial year. Decision: the CoG approved its Annual Business Plan for 2025/26. 3 6.5 Non-Executive Director Appointment The Chair reminded the CoG that at its meeting on 15 April 2024 it had approved the appointment of David Liverseidge as a NED, for a three-year term. However, due to his position at Ramsay Health Care UK and the potential conflict of interest, it had been agreed to delay his appointment until his retirement at the end of 2024. The CoG was therefore asked to note that following completion of the Fit and Proper Persons checks and declaration processes, his appointment as a NED had commenced on 1 January 2025. 6.6 Governor Attendance at Council of Governors’ Meetings KR introduced the report and advised that if a governor failed to attend two successive meetings of the CoG, their appointment would be terminated unless the absences were due to reasonable cause. The Chair, CM or KR would contact the governor, to understand the reasons and would then provide confirmation to the CoG that the causes were reasonable. BL said that he would find it difficult to approve the continued tenure of a governor, if he did not know the reasons for their absence. The Chair clarified that the CoG would be asked to confirm that it was satisfied the Chair or Company Secretary had followed the process, rather than be asked to approve the reasons for any absence. SG queried what was meant by a “reasonable period” and the Chair advised that it would depend on the circumstances, which would be discussed with the individual governor. Action: It was agreed that CM and KR would review the constitution to check whether any amendments to the wording were needed. 7 Membership Engagement and Governor Activity 7.1 Membership Engagement SD introduced the Membership Engagement report and highlighted the following:- • the monthly newsletters continued to keep members updated. • the quarterly Connect digital magazines had been sent out in November 2024 and January 2025. There had been an emphasis on health inequalities in the community, in the latter edition. • the open evening and annual members’ meeting had been held, in person, at UHS in November 2024. It had not been as well attended as he would have hoped (it had snowed that day) and going forward, ways to maximise attendance would be considered. However, there had been positive feedback from those who had attended. • during December 2024 a virtual event, focused on healthy ageing, had been held. He encouraged governors to register for the forthcoming virtual event on cancer research. • due to the extreme pressures on the hospital, the team had actively used social media channels to remind people of the alternatives available, rather than attending the emergency department. • the opening of Woodland Ward, special care baby unit at the Princess Anne Hospital, had featured in the quarterly update. • the continued production of the monthly updates and the Spring edition of the Connect quarterly digital magazine were priorities for the team. 4 • attendance at external events (e.g. the Mela Festival) and opportunities to collaborate with other teams, were being planned and governors were encouraged to offer their support. Governors made the following comments:• it was helpful to have an engaging activity available at external events, as these helped to draw people in. • whether it would be appropriate to attend the Southampton marathon, which attracted a large number of people. SD advised that the team had attended in the past but had not found it the ideal event to have conversations with people. He would, however, contact the hospital charity, to see whether there was information that could be handed out. • SL suggested that she and SD discuss ways to recruit students as members. The Chair thanked SD for his informative report. 7.2 Governors’ Nomination Committee Feedback The Chair advised that the Governors’ Nomination Committee had met on the 15 January. It had undertaken the annual review of its Terms of Reference and had looked at the appraisal process for the Chair and NEDs. It had also noted the commencement of David Liverseidge as a NED. 8 Review of Meeting The governors said that they had found the meeting very informative, with the right level of information provided. 9 Any Other Business The following were mentioned by governors:- • the increased aggression towards staff was noted and the Chair advised that greater detail would be available once the annual staff survey results were available. • KB advised that she had visited Heartbeat House (on the edge of the UHS site) where friends and relatives of patients undergoing cardiac surgery could stay. A coffee morning was held every Tuesday morning in Heartbeat House and KB encouraged governors to attend, as it provided a good opportunity to meet members of the public. She also raised awareness of the Heart & Stroll event being held on 29 June 2025 to raise funds towards the renovation of the Heart Failure Unit at UHS. • CM advised that due to changes in the Hampshire and Isle of Wight Integrated Care Board (ICB) and a possible conflict of interest, the ICB did not intend to replace Helen Eggleton, who had previously represented them as a governor on the CoG. It was therefore proposed to reduce the number of governors to 21, which would require the constitution to be amended. The CoG expressed its disappointment at the ICB’s decision and the Chair agreed to discuss the decision, when she next met with the Chair of the ICB. • the Chair advised that with effect from 11th March, all UHS Trust Board meetings would be held in person. A hybrid option would, however, still be available for the CoG meetings. • the Chair asked governors to ensure that they advised KR of any board committees they wished to attend, at least a week in advance. This would enable KR to liaise with the committee Chair, to ensure that it was appropriate for a governor to attend. 10 Date of Next Meeting The next meeting of the CoG would be held on 29 April 2025. 5 List of action items Agenda item Assigned to Deadline Status Council of Governors 29/01/2025 6.6 Governor Attendance at Council of Governors’ Meetings 1199 Governor Attendance at Council of Governors’ Meetings . Machell, Craig Russell, Karen 29/04/2025 Completed Explanation action item Under the Trust’s constitution if a governor failed to attend two successive meetings of the council of governors, his or her tenure of office is to be immediately terminated by the CoG unless the CoG is satisfied that the absences were due to reasonable cause; and he/she will be able to attend meetings of the CoG within such a period as the CoG considers reasonable. The CoG was happy to confirm it was satisfied that the correct process had been carried out but could not comment on the reasons for absence or their ability to attend future meetings within a reasonable period of time, as these had been a confidential part of the discussion with the governor. CM and KR agreed to look at the Trust's constitution to establish if an amendment was required to the wording regarding this. Explanation Russell, Karen The wording in the constitution relating to this issue requires amendment and this will be carried out when the Trust's constitution is reviewed during 2025/26. In the meantime, the wording in future papers relating to governor attendance at CoG meetings will be adjusted accordingly. Item 5.1 Report to the Council of Governors - 29 April 2025 Title: Chief Executive Officer’s Performance Report Sponsor: David French, Chief Executive Officer Author: Sam Dale, Associate Director of Data and Analytics Purpose (type an ‘x’ in the appropriate box(es)) (Re)Assurance Approval Ratification Information x Strategic Theme (type an ‘x’ in the appropriate box(es)) Outstanding patient Pioneering research World class people outcomes, safety and innovation and experience Integrated networks and collaboration Foundations for the future x x x Executive Summary: Information about Trust performance supports the Council of Governors in their role. This report is intended to inform the Council of Governors about aspects of the Trust’s performance. Contents: The Chief Executive Officer’s Performance Report is attached. Risk(s): N/A Equality Impact Consideration: N/A UHS Council of Governors April 2025 Chief Executive’s Performance Report 1. Purpose and Context The purpose of this report is to summarise the Trust’s performance against a range of key indicators. Where available, this report covers data from the period January to March 2025, noting that some performance data is reported further in arrears and therefore unavailable. As the organisation transitions to the national 25/26 NHS priorities, notable features of 24/25 quarter four include: • The financial position of the organisation remains extremely challenging as the trust prioritises the national request to live within its means despite restrictions on funding for emergency activity and elective growth. • Despite the economic challenges, the organisation continues to benchmark well for productivity measures including theatre utilisation and length of stay whilst recognising there remains an opportunity to go further. • The waiting list continued to grow in quarter four, however the trust has maintained performance on 18 week targets and reduced the volume of patients waiting over 65 weeks to a small cohort of services. • The organisation has maintained robust performance on cancer and diagnostic waiting times and anticipates that the validated year end position will place the organisation in the top quartile compared to peer organisations. • The volume of patients with no criteria to reside remains above 200 per day which continues to place a barrier on our bed availability. • The trust ranking for recommendation as a place to work has improved four places placing UHS at 18th out of 122 trusts. 2. Safety Infection Control Clostridium Difficile infection MRSA Bacterium infection Target 78.0% January 2025 39 35 74 70 40 24 33 7 0 January 2025 63.9% February 2025 44 12 56 46 33 19 27 5 0 February 2025 57.4% March 2025 54 25 79 59 43 25 36 2 0 March 2025 60.1% Performance against the emergency access target continues to be challenging with attendances growing by 3.2% compared to the previous financial year. In March 2025, 60.1% of patients spent less than four hours in the department which places the trust in the third quartile when compared to peer teaching hospitals. There is significant focus on improving this, with the plan based on two areas; improving decision making speed within the Emergency Department and improving timely flow from the department when patients need admission. The former is looking at consistency of practice, speciality in-reach into the department, and ensuring rotas reflect known peaks in attendance. The latter is looking at enhanced access, and increased pathways, to same day emergency care, flow and discharge throughout the hospital and embedding internal professional standards. Referral to Treatment (RTT) Target January 2025 % incomplete pathways within 18 weeks in month Total patients on a waiting list => 92% 62.0% 60,910 February 2025 61.5% 61,333 March 2025 62.5% 61,686 Whilst the trust continues to deliver more elective activity year on year, the RTT (referral to treatment) waiting list has continued to climb in each month of quarter four peaking at 61,686 at the end of the financial year. Despite this the organisation has maintained performance of 62% for the percentage of patients on the waiting list who are below 18 weeks. The trust ensures the appropriate prioritisation of our longest waiting patients with those of more urgent clinical need. The hospital reported just one patient waiting over 78 weeks in March 2025 due to the continued national delays for corneal tissue release. There were 21 patients waiting over 65 weeks - whilst some were also corneal transplant patients, others were services impacted by the prioritisation of urgent cancer patients or services managing unexpected emergency demand. Page 3 of 5 The trust is now transitioning focus to new 25/26 national waiting list targets. The organisation is committed to maintaining the strong improvements seen in 24/25 for theatre utilisation, length of stay reduction and optimisation of outpatient clinics. Alongside this, the organisation is closely reviewing referral trends and opportunities to manage them through increased advice and guidance. Cancer Target Faster Diagnosis - within 28 days 31 Day target - decision to treat to first definitive treatment 62 day target - urgent referral to first definitive treatment > =77% => 96% => 70% December 2024 83.6% 94.9% 82.2% January 2025 80.6% 95.1% 79.9% February 2025 84.4% 92.8% 72.1% The organisation continues to prioritise cancer patients and their treatments for all tumour sites and cancer types. The trust has maintained its strong performance against the 28 day faster diagnosis standard, consistently hitting the target and benchmarking in the top quartile compared to peer teaching hospitals across the country. Diagnostic capacity and the impact of provider referrals into UHS specialised services impacted our 62 day performance in February but unvalidated data provides assurance that the position has recovered to above 80% in March 2025. 5. Finance The financial environment remains extremely challenging for UHS. One off income received by the ICB and several technical adjustments have however helped reduce the scale of the deficit to £7m at the end of February 2025. This is £3.7m behind the annual plan of £3.3m deficit. The trust is targeting a breakeven position in March 2025 to ensure the deficit doesn’t further deteriorate and HIOW ICS can achieve a breakeven position for the year. The trust’s underlying position, so removing one off income, is significantly more challenging than this with an underlying deficit of c£6.5m per month. The organisation therefore continues to put significant focus on financial recovery with the aim of ensuring the organisation ‘lives within its means’ and makes progress towards the delivery of a breakeven run rate. The deficit drivers remain similar to those previously reported, focusing on three key areas: 1. Urgent and Emergency activity is in excess of block funding levels by c£2m per month. This has meant surge capacity has been required across all months of the financial year with peak usage in winter months. Demand management schemes are under development with HIOW ICS partners as part of agreeing plans for 2025/26 as is an increased funding envelope. 2. Non-criteria to reside numbers have increased to peaks of 250 from an average of 220. This is c20% of the trusts bed base and has a significant cost in addition to clinical risks of patient deconditioning and infection. This remains a focus of the inpatient flow programme. 3. Mental health patient demands have also increased noticeably over previous years with patients requiring enhanced levels of support often at a significant cost premium to the trust. UHS continues to work with system providers on improvements for this patient group. Despite these pressures however the trust has continued to ensure value for money remains an organisational priority with £73m of savings achieved YTD particularly focused on transforming services under the three workstreams of theatre optimisation, outpatients and inpatient flow. The trust also continues to overperform on the elective recovery target which supports financial sustainability via increased tariff income and helps support waiting list reduction targets. Currently 126% of 2019/20 levels of elective, daycase and outpatient first attendances are being delivered compared to a target of 113%. YTD this has generated over £26m of additional income for the trust. Page 4 of 5 Further to this the trust remains on target to spend its full capital allocation for 2024/25 totalling over £95m including £20m on decarbonisation and improved energy infrastructure which is externally funded. This continued investment in capacity, digital and infrastructure helps support continued ongoing financial sustainability and efficiency improvements. Despite the scale of the financial challenge the trust continues to look forward with optimism that our investments in infrastructure and transformation provide the right “foundations for the future”, including sustainable finances, and supporting “world class people, delivering world class care” as outlined in our strategy. 6. Human Resources Indicator Staff recommend UHS as a place to work Staff survey engagement score (out of 10) Q3 24/25 68.3% 7.0 Q4 24/25 66.4% 6.8 Trust wide, we have maintained our above average position across all the People Promise domains in the annual staff survey (Q3), with results remaining broadly unchanged from 2023 across all questions, with minimal improvements or declines which would be considered statistically significant. Year-on-year results over a three-year period shows there to be continued improvements in relation to satisfaction with immediate managers, opportunities for flexible working, appraisals, and increased confidence in reporting of incidences of unsafe practice, violence, bullying and harassment. However, we continue to see downward trends associated with civility and respect, and team dynamics which align to the themes in recent patient safety events and F2SU themes. Additionally, our national ranking for recommendation as a place to work has improved four places from last year, we now rank 18th out of 122 trusts, compared to 22nd in 2023. Participation rate has continued to decline to 39% from 41% in 2023, a 15% drop since 2022. This represents a total participation of 5,410 people out of a total eligible of 13,795 including subsidiaries. When reviewing the quarterly survey results, such as Q4 above, it must be noted that these results are less representative of views across UHS as we hear from less people. We maintain around a 20% response rate with quarterly surveys, hearing from 2,878 staff in Q4 out of an eligible 14,636 (this number is higher as more staff are eligible to participate in the quarterly surveys. WPL do their own quarterly survey so are not included). Indicator Target January 2025 Staff Turnover (internal target; rolling 12 month) Sickness absence 12 month rolling (internal target) 75% of staff in each area has received training, including neonatal medical team. • Trolley dashes. • Train the trainer. Progress Metrics Audit of compliance: • Has it been undertaken for the appropriate babies? • Was the frequency of observation undertaken correctly? • Was the score accurately calculated? • Did escalation take place if required? • Was the response to escalation appropriate? Quality Improvement Priority Four: Implementation of the National Safety Standards for Invasive Procedures (NatSSIPs) 2 at UHS. Core Dimension Patient Safety Rationale for Selection The new National Safety Standards for Invasive Procedures (NatSSIPs 2) represent the progression of the original NatSSIPs. The key aim to standardise, harmonise and educate (SHE) across organisations and procedural teams remains central to the NatSSIPs purpose. Critical changes include bolstered organisational standards and proportionate checks that recognise different levels of risk during major and minor invasive procedures, and the adaptions to processes that may be necessary in life-threatening situations. This standardisation, harmonisation and education goals are set out in the table below. Investigations into the increase of never events in 2023 and 2024 has identified that the majority of these had contributing factors related to stop points for safety. The key learning identified: All these factors will be addressed through NatSSIPs2 implementation. Safer invasive procedures is to be included as a local quality indicator by the ICB within the 2025/26 national contract. Key Aims • Establish a NatSSIPs oversight committee. • Set up an invasive procedures committee. • Establish the following workstreams: o Audit of stops point for safety in theatres and for minor procedures in outpatient and ward areas o Multi-disciplinary safety walkabouts o VLE and induction workstream • Education: recruitment of medical education led to set up simulation-based MDT training. • Patient involvement • NatSSIPs 8 and communications. • Stop points for safety staff resources. Progress Metrics • Increase in the completion of VLE stop points training. • Develop and implement a programme to deliver non-technical skills to the MDT. • All areas with a never event in the last two years have an up-to-date audit and action plan for compliance with NatSSIPs2. Quality Improvement Priority Five: Fundamentals of Care Core Dimension Patient safety Rationale for selection The term Fundamentals of Care (FoC) describes the eight standards that staff across the Trust have committed to in collaboration with the patient, to support the physical and emotional needs of patients’, relatives, and carers. This is not a new concept, it underpins the core values of what it means to be a healthcare professional, to truly ‘care’ and will build upon our achievements in year one. Operational challenges have led the workforce to become more task-focused and less person-focused, taking away from that personalised care experience but we are committed to changing that culture, following our trust value, Patients First. The FoC exemplifies how the interdisciplinary team connects and builds relationships with our patients, getting to know them and what matters to them as a person, not just as a patient, supporting and encouraging independence and rehabilitation from the beginning of their hospital stay. These activities are the essentials of our daily living such as personal hygiene, skin care, oral hygiene, toileting, eating and drinking, and mobilising. Communication is also essential and includes both listening and hearing patients, understanding what is important to them using communication tools they need, coming to shared decisions with patients about their care and recognising the diversity of our population, embracing accessibility for those with people with learning disabilities, sight/hearing loss or other disabilities, or if English may not be their primary language. In addition, the FoC encourages us as healthcare professionals to consider the whole person, support cultural, spiritual, mental health, emotional wellbeing and dignity needs of people we care for and those that matter to them. We know here at UHS that not everyone experiences this level of care, but we acknowledge the need to change the rhetoric from ‘we are busy’ to ‘we are never too busy to care’ empowering and educating our staff at all levels to challenge the ‘we have not got time’ rhetoric and ensure fundamental care is at the heart of what we do at UHS. Thus improving, patient care and experience. Key Aims We will grow the multi-disciplinary engagement and involvement in workstreams that embrace the FoC and encourage person centred to care. We will continue to pursue the digitalisation of the Friends and Family Test (FFT), using this data and the national inpatient and urgent and emergency care survey as a baseline, while linking with involved patients where required with to encourage feedback on the FoC. We will listen to the voice of our patients, their relatives, and carers to make sure their stories and experiences are heard by our workforce to encourage the organisation wide change. We will ensure the FoC will has clear and measurable improvement metrics as part of a live clinical quality dashboard that will afford ward managers and senior leaders, the opportunity to monitor, review and report on to FoC in their areas. We will embed the FoC into the matron walkabout and CAS processes, supported by consistent evaluation metrics that ask the patients about their experiences and encourage clinical areas to continually assess and evaluate the FoC in their areas through a self-assessment tool. We will enhance the availability of existing resources on our virtual learning wnvironment (VLE) in collaboration with our patient partners for all staff groups and embed the FoC into training across the organisation, to improve the knowledge, skills and awareness ensuring the delivery of quality care. We will continue to test and evaluate the What Matters To Me project, growing our volunteer role to support staff in finding out what is important to the patient and using their personalised board to remind staff of the ‘person’ they are caring for. We will continue to establish project links in child health, maternity and outpatients to ensure a bespoke, but collaborative roll out of FoC, considering how these different care environments may impact care. Progress Metrics • Patient hygiene – We will see an improvement in the number of patients who report having their personal care needs met, particularly within their first 24 hours coming through emergency admission routes. • Skin integrity – We will support the reduction in incidences of avoidable pressure ulcers across the organisation. • Communication – We see an increase in the number of people accessing our interpreting services and a reduction in complaints related to interpretation. • Pain – We will see an improvement in patients reporting that their pain was well controlled when coming through the emergency department. • Mouthcare – We will see a positive uptake in the implementation of the new mouthcare assessment tool and an improvement in patients reporting that their oral hygiene needs have been met. • Nutrition and hydration – We will see an increase in patients reporting they are being offered adequate food and drink provisions throughout their hospital stay, including access to equipment for those with conditions or disabilities that impact their ability to do so independently. • Bowel and bladder care – We will see improved assessment of bowel and bladder habits through increased documentation using the Inpatient Noting system. • Enhancing safe movement – We will support a reduction in the incidence of high harm falls and high harm falls that have preventable causes. • Infection prevention – We will see a reduction in nosocomial infections through increased hand hygiene standards and more effective cleaning of equipment Quality Improvement Priority Six Develop the Trusts’ approach to reducing the impact of health inequalities (HIs) - year two. Core Dimension Clinical effectiveness Rationale for selection Tackling health inequalities is a key priority for the NHS. At UHS we have been working to have an impact on health inequalities for several years. In 2024/25 we formalised these efforts with a governing board, chaired by our chief medical officer and with a clear programme of improvement based on recognised priorities. This formed the basis of our quality priority in 2024/25. This year’s quality priority is a continuation of the work that started in 2024/25. We intend to continue to grow our understanding and actions as an organisation, improving the equity of access, outcomes and experience of our services across our community. Key Aims We are continuing our health inequalities board, with focus on five priorities: enabling our organisation, data and measurement, clinical service priorities, communication and engagement and strategy and approach. Each of these priorities have aligned directors to oversee improvement and a detailed delivery plan. Key priorities and expected outcomes from each of these are listed below: Enabling the organisation: • Developing supporting structures - set up governance so that teams who identify health inequality related issues know where they can go for help, so that we can understand frequently arising challenges and notice when a problem raised might be affecting other of the hospital too. This will aid improvement, learning from issues identified and escalation of issues that cannot be resolved locally • Capability building - develop training for our staff to understand health inequalities, identify them within services and access tools to make improvement. • Delivery of the health inequalities officer role - grow knowledge of the health inequalities officer role across the organisation and utilise this role to share knowledge, training and support improvements. Data and measurement • Continue to develop our understanding of inequalities in access across outpatients and diagnostics, inpatients, theatres and the emergency department. • Enable the measurement of improvement in areas recognised as clinical priorities. • Enable completion of national reporting. Clinical priorities • Improve services and support for patients and staff with obesity (children and adults). • Improve identification and control of hypertension. • Improve services and support for patients and staff who smoke. Communication and engagement • Adopt health inequalities into leadership and decision making. • Learning from our communities and our staff. • Communicating improvements internally and externally. • Staff support campaign. Strategy and approach • Overseeing and agreeing UHS approach and strategy for HIs. • Overseeing annual delivery against priorities. • Aligning programme resource. • Maintaining collaborative working with public health and Integrated Care Board teams and other local healthcare providers. • Keeping up to date with national recommendations and expectations, sharing this knowledge with our organisation. • Overseeing trustwide improvement and health inequalities maturity. Progress Metrics • Increasing numbers of staff trained. • Numbers of health inequalities issues reported (expected to increase through understanding before reducing due to improvement work). • Case studies shared of successful improvement projects. • Increased involvement and collaboration with patients and public on improvement. • Increased use of QEIA templates in decision making. • Demonstration of improved access to care for obesity, tobacco dependency and hypertension. 2.3 Statements of assurance from the Board This section includes mandatory statements about the quality of services that we provide relating to the financial year 2024/25. This information is common to all quality accounts and can be used to compare our performance with that of other organisations. The statements are designed to provide assurance that the board of directors has reviewed and engaged in cross-cutting initiatives which link strongly to quality improvement. 2.3.1 Review of services During 2024/25 UHS provided and/or sub-contracted 118 relevant health services (from total Trust activity by specialty cumulative 2024/25 contractual report). UHS has reviewed all the data available to them on the quality of care in all these relevant health services. The income generated by the relevant health services reviewed in 2024/25 represents 100% of the total income generated from the provision of relevant health services by UHS for 2024/25. 2.3.2 Participation in national clinical audits and confidential enquiries The UHS clinical audit programme was developed in support of the Trust’s vision by putting patients first, working together and always improving. This leads on to a specific strategy for clinical outcomes, to ensure robust and measurable processes are in place to plan locally and participate strategically. Healthcare Quality Improvement Partnership (HQIP) produces a National Clinical Audit & Enquiries Directory which identifies those national audits which are included in the NHS England Quality Account List 2024/25, those audits which are part of National Clinical Audit and Patient Outcomes Programme (NCAPOP). NCAPOP audits are commissioned and managed on behalf of NHS England by HQIP. These collect and analyse data supplied by local clinicians to provide a national picture of care standards for that specific condition. On a local level, NCAPOP audits provide local trusts with individual benchmarked reports on their compliance and performance, feeding back comparative findings to help participants identify necessary improvements for patients. The audits listed on the NCAPOP are ‘must-do’ national audits. The quality accounts national clinical audit list includes audits which we regard as ‘best practice’ to participate in (in addition to those from the NCAPOP) and for that reason we always include these in our corporate audit plans as a priority where they are relevant to our Trust. UHS has a strong history for completing clinical audits. The clinical effectiveness team has a robust approach to governing and supporting the completion. We’ve opened discussions with senior clinical leadership within Hampshire and Isle of Wight Integrated Care Board regarding the current challenges with contributing to and using the outputs of national audits. Benchmarked data resulting from national audits provides strong guidance on areas of excellence and improvement, however completion can be challenging in its complexity and resource intensiveness, and timeliness of outputs can reduce our ability to be responsive to indications. Real time data supports our clinical teams to be proactive in striving to meet our always improving objectives. During 2024/25 68 national clinical audits and four national confidential enquiries covered NHS services that UHS provides. During 2024/25 UHS participated in 97% of national clinical audits and 100% national confidential enquiries of which it was eligible to participate in. NCEPOD studies participated in during 2024/25 were: • Emergency (non-elective) surgery in children and young people. • Juvenile idiopathic arthritis. • Blood sodium (hyponatraemia). • Acute Limb Ischaemic. UHS fully supports the Maternal, Newborn and Infant Clinical Outcome Review Programme (MBRRACE-UK) and all the reviews that take place under this umbrella. The national clinical audits that UHS participated in, and for which data collection was complete during 2024/25, are listed below (Table A) alongside the number of cases submitted to each audit or enquiry as a percentage of the number of registered cases required by the terms of that audit or enquiry if known at time of writing this report. Eligible (68) Participated 66 = 97%) Table A. Total number of NCAs UHS were eligible to participate in (n=68) % Actual cases submitted / expected submissions 1. BAUS Penile Fracture Audit ✓ Not yet started 2. BAUS I-DUNC (impact of Diagnostic Ureteroscopy on Radical ✓X Nephroureterectomy and Compliance with Standard of care practices) 3. BAUS Environmental lessons learned and applied to the bladder cancer ✓ care pathway audit (ELLA) 4. Breast and Cosmetic Implant Registry ✓✓ 5. Case Mix Programme (CMP) (ICNARC) ✓✓ 1677 for 3 quarters 6. Emergency Medicine QIPs – Time critical medications ✓✓ 63 pts 7. Emergency Medicine QIPs – Care of older people ✓✓ 182 pts 8. Falls and Fragility Fractures Audit Programme (FFFAP) national hip ✓✓ 971 all pts fracture database 9. Falls and Fragility Fractures Audit Programme (FFFAP) fracture liaison ✓ ✓ 2910 all pts database 10. Falls and Fragility Fractures Audit Programme (FFFAP) National Audit of ✓ ✓ Inpatient Falls 11. Learning disability and autism programme - Learning from lives and ✓✓ 100% deaths of people with a learning disability and autistic people (LeDeR) 12. National Adult Diabetes Audit – National Diabetes Inpatient Safety ✓✓ audit 13. National Adult Diabetes Audit – National Pregnancy in Diabetes ✓✓ 100% 14. National Diabetes Audit - transition ✓ ✓ Collects data from database 15. National Diabetes audit – gestational diabetes ✓ ✓ Collects data from database 16. National respiratory Audit Programme (NRAP) - asthma in children ✓✓ 17. National respiratory Audit Programme (NRAP) - asthma in adults ✓✓ 18. National respiratory Audit Programme (NRAP) - COPD secondary care ✓ ✓ 19. National respiratory Audit Programme (NRAP) Pulmonary rehabilitation ✓ ✓ 20. National Audit of Care at the End of Life (NACEL) ✓✓ 250 pts 21. National Cancer Audit Collaborating Centre - National Audit of ✓ ✓ Data entry not Metastatic Breast Cancer required 22. National Cancer Audit Collaborating Centre - National Audit of Primary ✓ ✓ collected Breast Cancer nationally 23. National Cancer Audit Collaborating Centre – National Kidney Cancer ✓✓ Audit (NKCA) 24. National Cancer Audit Collaborating Centre – Non-Hodgkin Lymphoma ✓ ✓ Audit (NNHLA) 25. National Cancer Audit Collaborating Centre –National Pancreatic ✓✓ Cancer Audit 26. National Cancer Audit Collaborating Centre - National Bowel Cancer ✓✓ Audit (NBOCA) 27. National Cancer Audit Collaborating Centre - National Oesophago- ✓✓ gastric Cancer (NOGCA) 28. National Cancer Audit Collaborating Centre - National Lung Cancer ✓✓ Audit (NLCA) 29. National Cancer Audit Collaborating Centre - National Prostate Cancer ✓ ✓ Audit (NPCA) 30. National Cardiac Arrest Audit (NCAA) ✓✓ 150 Approx 31. National Cardiac Audit Programme (NCAP) - Adult cardiac surgery ✓✓ 32. National Cardiac Audit Programme (NCAP) - Cardiac Rhythm ✓✓ Management (CRM) 33. National Cardiac Audit Programme (NCAP) - congenital heart disease ✓✓ (CHD) paeds 34. National Cardiac Audit Programme (NCAP) - Heart Failure audit ✓✓ 35. National Cardiac Audit Programme (NCAP) - Acute Coronary Syndrome ✓ ✓ 100% or Acute Myocardial Infarction 36. National Cardiac Audit Programme (NCAP) - Percutaneous coronary ✓✓ 100% interventions (PCI) 37. National Cardiac Audit Programme (NCAP) - The UK Transcatheter ✓✓ Aortic Valve Implantation (TAVI) Registry 38. National Cardiac Audit Programme (NCAP) -Left Atrial Appendage ✓✓ Occlusion (LAAO) Registry 39. National Cardiac Audit Programme (NCAP) – Patent Foramen Ovale ✓✓ Closure (PFOC) Registry 40. National Cardiac Audit Programme (NCAP) – Transcatheter Mitral & ✓✓ Tricuspid Valve (TMTV) Registry 41. National Child Mortality Database (NCMD) ✓✓ 100% 42. National Clinical Audit of Seizures and Epilepsies for Children and ✓✓ *1 pt Young People (Epilepsy12) 43. National Comparative Audit of Blood Transfusion – Audit of NICE ✓✓ Quality Standard QS138 44. National Comparative Audit of Blood Transfusion – Bedside Transfusion ✓ ✓ Audit 45. National Early Inflammatory Arthritis Audit (NEIAA) ✓✓ 46. National Emergency Laparotomy Audit (NELA) - Laparotomy ✓✓ 47. National Emergency Laparotomy Audit (NELA) – No lap ✓✓ 48. National Joint Registry ✓ ✓ 834 (data run to 10/02/2025) 49. National Major Trauma Registry ✓ ✓ 600 for 3 quarters 50. National Maternity and Perinatal Audit (NMPA) ✓✓ 51. National Neonatal Audit Programme (NNAP) (Neonatal Intensive and ✓✓ 100% Special Care) 52. National Ophthalmology Audit Database ✓✓ 53. National Paediatric Diabetes Audit ✓✓ 54. National Vascular Registry (NVR) ✓✓ **100% 55. Paediatric Intensive Care Audit Network (PICANet) ✓✓ 100% 56. Perinatal Mortality Review Tool (PMRT) ✓✓ 100% 57. Perioperative quality improvement programme ✓✓ 12 pts 58. Quality & Outcomes in Oral & Maxillofacial Surgery (QOMS) – Oncology ✓ Data taken & reconstruction straight from 59. Quality & Outcomes in Oral & Maxillofacial Surgery (QOMS) – Trauma ✓ other 60. Quality & Outcomes in Oral & Maxillofacial Surgery (QOMS) – ✓ databases Orthognathic surgery 61. Quality & Outcomes in Oral & Maxillofacial Surgery (QOMS) – Non- ✓ melanoma skin cancers 62. Quality & Outcomes in Oral & Maxillofacial Surgery (QOMS) – Oral & ✓ Dentoalveolar Surgery 63. Sentinel Stroke National Audit Programme (SSNAP) continuous SSNAP ✓ ✓ Clinical patient Audit, organisational audit 64. Serious Hazards of Transfusion (SHOT) UK National haemovigilance ✓✓ scheme 65. Society for Acute Medicine's
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-29.04.2025-v2.pdf

1 to 3 of 3

Browse site A to Z

Search results

Current funding calls

UHS register of interests June 2025

Papers CoG 29.04.2025 v2

Site policies

Contact details

Useful links